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ABBREVIATIONS
Ab(s) antibody(ies)
Ag antigen
BCR B Cell Receptor
BM Bone Marrow
bp Base pair
BSA Bovine Serum Albumin
CD cluster of differentiation
cDNA Complementary DNA
CG Chicken γ-globin
CyC CyChrome
DMEM Dulbecco’s Modified Eagle’s Medium
DMSO dimethylsulfoxide
DNA deoxyribonucleic acid
Dnase deoxyribonuclease
DNTP 2’ deoxyribonucleosidetriphosphate
DTT dithiothreitol
EDTA ethylene-diaminetetraacetic acid
ELISA enzyme-linked immunosorbent assay
EF embryonic fibroblasts
ES cells embryonic stem cells
FACS fluorescence activated cell sorter
FCS fetal calf serum
FITC fluorescein isothiocyanate
Flox loxP flanked region
FSC forward scatter
G418 geneticin
Ig immunoglobulin
IL interleukin
i.p. intaperitoneal
i.v. inteavenous
kb kilobase pairs
LIF leukemia inhibitory factor
LPS lipopolysaccharide
2-ME 2-mercaptoethanol
MACS magnetic cell sorting
MHC major histocompatibility complex
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mmC mitomycin-C
mRNA messenger RNA
neor neomycin resistance
NP 4-hydroxy-3-nitrophenylacetyl
OD optical density
PBS phosphate buffered saline
PCR polymerase chain reaction
PE phycoerythrin
PFU plaque forming units
RAG recombination activating gene
RNA ribonucleic acid
rpm revolutions per minute
RPMI Rosewell-Park-Memorial-Institute cell culture medium
RT Room temperature
SA streptavidin
SDS sodium dodecyl sulfate
TCR T cell receptor
Tg transgenic
Tk thymidine kinase
Tris Tris(hydroxymethyl)aminoethane
UV ultraviolet
VSV Vesicular stomatitis virus
wt wild type
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1. Introduction
The immune system has evolved in vertebrates for the protection of the organism against
foreign, potentially pathogenic, microorganisms or parasites. The vertebrate immune
system consists of an innate and an adaptive component. The innate immune system
functions as a first line of defence against a broad range of pathogens. The adaptive
immune system, on the other hand, is characterised by high specificity, ability ‘to learn’
and memory. Invasion of any foreign agent elicits an immune reaction, which can be
divided into two interrelated activities, recognition and response.
Recognition by the adaptive immune system is ‘precise’. It has evolved so as to
recognise foreign, non-self components with high specificity. Subtle differences in the
protein or polysaccharide content of invading microorganisms can be detected and
subsequently lead to a different response.
The goal of the elicited immune response is the most efficient clearance of the invading
agent. Two distinct, although tightly interdependent, processes can be activated: humoral
and cellular responses. The key effectors of the humoral immune response are B
lymphocytes, while T lymphocytes are mostly involved in the cellular response pathway.
1.1 B Lymphocytes
1.1.1 Antibodies and the B Cell Receptor (BCR)
B cells are the key effectors of the humoral immune response since they can produce
antibodies. Antibodies are tetrameric protein molecules composed of immunoglobulin
heavy and light chain heterodimers. Disulfide bonds link the heavy chains, but also exist
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between heavy and light chains. Each chain has a constant region (C) and a variable
region (V); the variable region is highly divergent and mediates antigen recognition and
binding. The constant region is conserved, although there are several IgH constant
region variants, termed immunoglobulin isotypes (α,δ,ε,γ) and two different light chains
(κ and λ) (Honjo and Alt, 1995).
B cells can secrete antibody but additionally express it on their surface (surface immuno-
globulin or sIg), anchored to the membrane. Surface immunglobulin associates with the
Igα /Igβ heterodimer which functions as a signal transducing entity. Surface Ig together
with Igα /Igβ forms the B Cell Receptor (BCR) (Reth, 1992) (Schamel and Reth, 2000)
(Figure 1).
Figure 1: The murine BCR consists of two identical heavy chains (of any isotype: µm, δm, εm, γm
and αm; shown here is µm) and two identical light chains (κ or λ) which form the membrane bound
immunoglobulin (mIg). The mIg can bind antigen specifically with its variable region (shown in
grey) whereas the membrane proximal and transmembrane constant region (shown in white)
associates with an Igα/Igβ heterodimer. These molecules contain tyrosine based activation motifs
(known as ITAMS) in their cytoplasmic tails thereby coupling the receptor to intracellular
signalling molecules.
Depending on the developmental status and the micro environment of the B cell, the
strength and quality of BCR transmitted signals control survival, differentiation and
proliferation (Healy and Goodnow, 1998; Nemazee, 2000).
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1.1.2 B cell development
The governing force in B cell development is the generation of B cells expressing a B
cell receptor on their surface and subsequently ensuring that this BCR does not
recognise self-antigens. In mice and humans, B cell generation occurs during
embryogenesis in liver and spleen. After birth, it is largely restricted to the bone marrow.
 B cell development in the bone marrow can be divided into distinct steps that are easily
identified by the differential expression of surface antigens (Figure2; Hardy et al., 1991;
Rajewsky, 1996).
Figure 2: B cell development in the bone marrow. Classification of the various fractions is primarily
defined by the rearrangement status of the immunoglobulin heavy and light chains and by the
expression pattern of surface markers (adapted from Hardy et al., 1991).
In most cases, B cells synthesize first a heavy chain, which is expressed on the surface
of the cells together with surrogate light chains (VpreB and λ5) (Sakaguchi and
Melchers, 1986; Takemori et al., 1990) and Igα/Igβ; this complex is known as the pre-B
cell receptor and is essential in signalling for cell survival and progression to the
precursor (pre-) B cell stage (Kitamura et al., 1991). Light chain is subsequently
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produced in pre-B cells, and substitutes the surrogate light chains (Coffman and
Weissman, 1983) thus forming the BCR. Immature B cells express a BCR of a single
specificity on their surface. Monospecificity is achieved by two processes, termed allelic
exclusion and light chain isotype exclusion (Gorman and Alt, 1998) (see Chapter 1.5)
which ensure that each lymphocyte expresses Ig protein from only one heavy and light
chain locus and thus produces an antigen receptor of a given specificity.
The specificity of the receptor is controlled before cells leave the bone marrow, in order
to select against autoreactive B cell receptors. These are eliminated either by
modification of the receptor (see Chapter 1.6) or deletion of autoreactive B cells
(Nemazee and Buerki, 1989).
1.1.3 B cells in an immune response
Mature Ig expressing B cells (IgM+, IgD+) then leave the bone marrow and migrate to
peripheral lymphoid organs, where they persist for weeks or months. These B cells can
become activated upon encounter with antigen. Multimeric antigens often directly
stimulate B cell proliferation and differentiation into antibody producing plasma cells by
cross-linking of the BCR, while protein antigens require T cell help for B cell activation
(reviewed in Rajewsky, 1996).
In a T cell dependent response an oligoclonal population of antigen activated B cells
starts proliferating and differentiating in primary follicles located in peripheral lymphoid
organs. This requires the presence of antigen specific helper T cells and follicular
dendritic cells (FDC). Rapidly expanding antigen-activated B cells form a structure
known as germinal centre, where they undergo isotype switching, affinity maturation
and terminal differentiation into plasma and memory cells. Naïve IgM+IgD+ cells
recruited to the germinal centre can switch to synthesis of other immunoglobulin
isotypes (IgG, IgE, IgA) (Esser and Radbruch, 1990). These cells additionally diversify
their Ig receptor by directed point mutations of the Ig heavy and light chain genes (Jacob
et al., 1991). This later process is called somatic hypermutation and is mediated by a yet
elusive enzyme, possibly an error prone DNA polymerase (Goodman and Tippin, 2000).
Mutation of Ig heavy and light chains generates a pool of different antibody specificities,
which are then selected for their ability to bind the immunogenic antigen with higher
affinity, while potentially autoreactive and low affinity mutants are eliminated (Allen et
al., 1987; Berek, Jarvis and Milstein, 1987).
The process of affinity maturation contributes to the diversity of the secondary antibody
repertoire, but already before, in the naïve B cell compartment a large number of diverse
receptor specificities are present. The specificity is conferred to the BCR by the variable
region of immunoglobulin heavy and light chains.
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1.2 Generation of antibody diversity
The enormous diversity of antigen receptors is primarily achieved by random assembly
of the variable region of both heavy and light chain genes by a ‘cut-and-join’ process
known as V(D)J recombination.
Both heavy and light chains are not single gene entities; they are composed of a different
number of gene segments, which have to be assembled in order to produce the functional
protein. Genes encoding Ig heavy chains (IgH genes) are formed by first rearranging a
DH to a JH element. Upstream VH elements are then recombined to the DHJH joint in order
to form a VHDHJH segment, which codes for the variable region of the IgH (Figure 3).
Assembly of the light chain is simpler, since only a VL to JL joint has to be formed
(Figure3).
The murine heavy chain locus contains between 100-1000 VH elements (Honjo and Alt,
1995), about 15 DH elements (Chang, Paige and Wu, 1992) and 4 JH elements. The κ
light chain locus consists of 93 Vκ and 5 Jκ gene segments (Thiebe et al., 1999) whereas
the λ locus has a different structure with three functional subsets of V, J and C elements.
The ‘random’ rearrangement of these modules in order to generate the variable region of
IgH and IgL molecules is mainly responsible for the observed diversity of the antibody
repertoire. Another phenomenon, which contributes to the diversity of the antibodies
produced, is the random deletion or addition of untemplated nucleotides, called N and P
nucleotides, at V(D)J junctions .
Figure 3: Organisation of the murine immunoglobulin heavy and light chain loci and schematic
representation of the steps necessary to form a variable region (adapted from Kuby).
These recombination events take place in the bone marrow: heavy chain rearrangement
generally occurs first, in pro-B cells (or using a different nomenclature cells of Fraction
A-C’), while light chain rearrangement follows in the pre-B cell compartment (Fraction
D) (Hardy et al., 1991; ten Boekel, Melchers and Rolink, 1995).  Recombination is not
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precise, often leading to out of frame coding units. These recombination events are
termed non-productive. If on the other hand, the joints are in a contiguous open reading
frame, the rearrangements are referred to as productive. Statistically, less than one third
of possible rearrangements leads to a productive joint and therefore to a full-length
protein.
1.3 Effectors of V(D)J recombination: the RAG proteins
Many of the enzymes involved in V(D)J recombination have been identified; most of
them are ubiquitously expressed double strand break repair enzymes (Ku70, Ku80,
DNAPKcs, XCCR4 and DNA ligase IV proteins) (Critchlow and Jackson, 1998) but two
are lymphoid lineage specific proteins, named Recombination Activating Genes (RAG1
and RAG2). The RAG proteins were identified about fifteen years ago as the only
necessary components for the recombination event (Oettinger et al., 1990; Schatz and
Baltimore, 1988). Co-transfection of RAG-1 and RAG-2 expression constructs is
sufficient for recombination to occur in many non-lymphoid cell lines. These proteins
specifically recognise and bind to conserved sequence motifs flanking the V, D and J
segments, named Recombination Signal Sequences (RSS)(Sakano et al., 1979). RSSs
are composed of a conserved heptamer, a relatively non-conserved spacer region of 12
or 23 bp and a conserved nonamer (Figure 4a).
The stoichiometry of the reaction is not accurately known, but two RSS sequences, with
different spacer regions (12/23 bp rule) (van Gent, Ramsden and Gellert, 1996) are
brought together, possibly by two RAG-1/RAG-2 complexes (tetramer consisting of two
molecules of each RAG protein) (Bailin, Mo and Sadofsky, 1999). RAG-1 mediates
RSS recognition primarily through the nonamer, with a region which is homologous to
the DNA-binding domain of bacterial invertases, such as Hin, and to homeodomain
proteins (Difilippantonio et al., 1996; Spanopoulou et al., 1996). The DNA-bound RAG-
1 recruits RAG-2 and high mobility group proteins (HMG-1, HMG-2) (Aidinis et al.,
1999) to the complex. No sequence-specific binding of RAG-2 to DNA has been
reported, but the binding of RAG-1 is enhanced by recruitment of RAG-2 and the
protein-DNA contacts are then extended into the heptamer region (Swanson and
Desiderio, 1998). These contacts seem to distort the DNA around the heptamer-coding
region and nicking occurs at the border of the heptamer and the coding sequence; this is
followed by a transesterification reaction in which the free 3’ hydroxyl group attacks a
phosphodiester bond on the opposite strand (van Gent, Ramsden and Gellert, 1996). As
a result, two DNA ends are produced: a signal end terminating in a 5’-phosphorylated,
double strand break and a coding end terminating in a hairpin. The ligation of the signal
end, which occurs at the base of the two heptamers is relatively precise but the coding
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joint is deliberately imprecise. The hairpin structure after nucleolytic opening can
function as a substrate for deletion of nucleotides or the addition of untemplated (N)
nucleotides by terminal deoxynucleotidyl transferase (TdT) (Desiderio et al., 1984;
Grawunder and Lieber, 1997). Additionally, short stretches of palindromic (P)
nucleotides are generated from asymmetric opening of the hairpin coding ends,
producing self-complementary single stranded extensions that can be incorporated into
the coding joints (Lewis, 1994).
Studies of artificial recombination substrates have shown that the RSSs are both
necessary and sufficient to direct V(D)J recombination. Plasmid substrates containing
RSSs can efficiently recombine in cells transfected with RAG expression vectors (Hesse
et al., 1987). The recombination signal sequences are asymmetrical and their orientation
is important for the recombination event. Depending on the orientation of the RS
sequences, recombination can lead either to deletion or inversion of the intervening
DNA (Figure 4b).
Figure 4: a) The signal sequences consist of a conserved palindromic heptamer and a conserved AT-
rich nonamer; these are separated by non conserved spacer regions of either twelve or twenty-three
base pairs b) Depending on the orientation of the RSS sequences RAG recombination can lead to
deletion or inversion of the intervening substrate.
Both deletional and inversional recombination events occur in vivo. Deletion is more
common and takes place during the assembly of the IgH chain and T Cell Receptor loci,
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while inversion has been detected in the human and the murine, Igκ locus (Honjo and
Alt, 1995; Thiebe et al., 1999).
1.4 Control of V(D)J Recombination
One of the fascinating aspects of VDJ recombination is that there is a strict temporal and
tissue specific control of the recombination events. Developing lymphocytes harbour
seven complex immune receptor loci (four T Cell Receptor and three Ig) that are
rearranged by a common recombinase. RAG proteins are expressed throughout B cell
development in the bone marrow, and are also expressed in developing thymocytes (for
the rearrangement of TCR loci). Yet, complete rearrangement of Ig loci occurs
exclusively in B cells and of TCR loci in T cells (Alt et al., 1992). Furthermore, the
rearrangement proceeds in an ordered fashion: in developing B cells IgL loci will start
rearranging mainly after productive assembly of the IgH locus (Alt et al., 1981) and a
similar phenomenon is observed in T cells. To explain the apparent paradox that
recombination does not readily occur, although both the necessary enzymes (RAG1,2)
and the substrate for the reaction are present, the ‘accessibility hypothesis’ was
formulated.
This hypothesis postulates that Ig and TCR genes typically reside in a chromatin
structure that is refractory to recognition by the recombination machinery (Alt,
Blackwell and Yancopoulos, 1987; Yancopoulos and Alt, 1986). In lymphoid cells,
developmental signals lead to changes in chromatin that allow the recombinase access to
particular gene segments but not to others. To test this hypothesis the overall
configuration of rearranging versus non-rearranging loci was analysed. Hence it was
reported that active V(D)J recombination correlates with transcriptional activity, DNA
demethylation, and increased DNaseI sensitivity of the rearranging loci, all of which can
be considered hallmarks of chromatin remodelling.
Although all three of these features have been associated with enhanced V(D)J
recombination, none of them perfectly predicts which joining signals will be available
for rearrangement. Germline transcription, for example, from unrearranged VH gene
segments can be detected just prior to heavy chain rearrangement (Yancopoulos and Alt,
1986) and seems to correlate with preferential usage of certain VH elements. Such
germline transcripts cannot be detected in B cells that have already rearranged their IgH
locus (Mather and Perry, 1981 ). Also transcription and recombination seem to correlate
well in several inducible systems (Schlissel, Corcoran and Baltimore, 1991), but
rearrangement in the absence of detectable transcription has been found in other cases
(Lauster et al., 1993)(Engler et al., 1991).
Nuclease sensitivity provides another means of monitoring changes in chromatin config-
uration. Studies with introduced substrates support a relationship between DNaseI
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sensitivity and recombination (Ferrier et al., 1989) while DNAseI hypersensitive sites
appear in TCR or Ig loci early in lymphoid differentiation (Blasquez et al., 1992).
The methylation patterns of Ig and TCR loci also change during lymphocyte
development. Such changes might be important for accessibility of the locus to V(D)J
recombination. Introduced Vκ transgenes can recombine in both B and T lineage cells,
and -unlike endogenous loci- are hypomethylated in both cell types (Goodhardt et al.,
1993). In T cells, there is a correlation between hypomethylation of the TCRβ locus,
which is tissue specific and established just prior to the onset of rearrangement, and the
subsequent rearrangement of the locus (Burger and Radbruch, 1990). Currently it is
believed that methylation per se does not bar access to the recombination machinery but
can function as a signal that will switch the chromatin into an inaccessible state after
replication (Hsieh and Lieber, 1992).
Recently the accessibility of RS sequences for RAG recombination has been correlated
to chromatin remodelling, either via histone acetylation or chromatin remodelling
factors, such as the Swi/Snf complex (Hernandez-Munain, McMurry and Krangel, 1999;
McBlane and Boyes, 2000; McMurry and Krangel, 2000). At the molecular level, it has
been shown that the position of the RSS nonamer and heptamer on the nucleosome
affects RAG binding and cleavage (Golding et al., 1999).
The exact way, however, in which chromatin remodelling is orchestrated in order to
allow or prohibit V(D)J recombination is not well understood. The emerging picture is
that in B and T cell development, during which substantial changes in gene expression
occur, Ig and TCR loci are also modified, in order to become accessible substrates for
V(D)J recombination.
1.5 Allelic exclusion
Regulating access of the RAG recombination machinery in Ig loci is crucial for yet
another phenomenon, called allelic exclusion. As mentioned previously, and as predicted
by the clonal selection theory (Burnet, 1976) B cells express an immunoglobulin
receptor (and therefore secrete antibody) of a given specificity. This requirement of
monospecificity means that of all Ig heavy and light chain loci present in a cell (a total
of six: two heavy chain alleles and four light chain alleles) only one heavy and one light
chain locus should produce functional protein. Repression of the production of other Ig
molecules is known as allelic exclusion, since it is achieved by restricting expression to
one of the two alleles from each locus.
Several models have been proposed to explain the phenomenon of allelic exclusion. The
stochastic model suggests that allelic exclusion of IgH loci is a secondary effect, due to
the low probability of two productive VHDHJH rearrangements occurring in one cell
(Coleclough et al., 1981). In a second model, it was postulated that expression of two
different IgH chains on the surface of the cells is toxic (Wabl and Steinberg, 1982), and
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thus double producers are eliminated. Heavy chain toxicity however, seems unlikely
since B cell generation is not impaired in transgenic mice producing two functional
heavy chains (Sonoda et al., 1997). Yet, the increased probability of generating an
autoreactive receptor, when two different heavy chains are produced, might further limit
the number of double producers.
Allelic exclusion is obviously favoured by both the limited time available for productive
rearrangements to occur and the counter-selection of autoreactive cells, but it is actually
established as a partial block of V(D)J recombination. In pro-B cells both IgH chain
alleles start DH→JH rearrangements but VH→DHJH joining typically occurs only on one
allele. If this is productive, it leads to expression of µ heavy chain on the surface of the
cells together with surrogate light chains (VpreB and λ5) (Sakaguchi and Melchers,
1986; Takemori et al., 1990) and Igα/β. Expression of this pre-BCR, as it is called,
seems to be critical for inhibiting further VH→DHJH rearrangements. Analysis of µ chain
transgenic mice show that, in fact, VH→DHJH rearrangements of endogenous loci are
greatly reduced while DHJH joints are still formed (Rusconi and Kohler, 1985;Weaver et
al., 1985). Gene knockout experiments have also shown that disruption of either the λ5
gene (Loffert et al., 1996) or the membrane exon of the µ chain on one allele (Kitamura
and Rajewsky, 1992) leads to impairment of allelic exclusion.
On the other hand, if the VH→DHJH joint on one IgH allele is not productive then
rearrangement of the other allele is mandatory for cell survival (Kitamura et al., 1991).
The pro-B cells that manage to express a pre-B cell receptor, subsequently move on to
start rearranging their light chain genes (Reth et al., 1987). Generally, but not always
(Novobrantseva et al., 1999; Zou, Takeda and Rajewsky, 1993) light chain
rearrangement also proceeds in an ordered fashion: one of the two Igκ alleles starts
rearranging first. If this is not productive or is unable to pair with the IgH chain, then
there is rearrangement of the other Igκ allele and only if this is equally unsuccessful,
recombination will proceed on the Igλ alleles (Hieter et al., 1981) (Muller and Reth,
1988).
This ordered process of rearrangement of the Ig loci yields B cells, which have one BCR
specificity. Analysis of the rearrangement “status” of peripheral B cells is a good
indication of the progression of cells through the sequential steps of V(D)J
recombination. Most cells harbour DHJH rearrangements on both alleles, while about
40% of them have a productive and a non productive VHDHJH joint. Only about 0.1% of
the cells have productive VDJ rearrangements on both heavy chain alleles (Barreto and
Cumano, 2000).
Although allelic exclusion depends on signals coming from the pre-BCR (Papavasiliou
et al., 1995), the exact mechanism of inhibiting rearrangement of a previously active
locus is not known. Signals from the pre B cell receptor initially lead to down-regulation
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of Rag gene expression (Grawunder et al., 1995) but this cannot be sufficient for the
establishment of allelic exclusion, since RAG proteins are again present during light
chain rearrangement. Somehow, changes in chromatin structure must be induced to
render the locus inaccessible to the recombinase.
1.6 RAG expression in peripheral B cells
B cell receptor expression on newly generated B cells marks a second ‘checkpoint’ in B
cell development. The successfully rearranged heavy and light chains now have to be
screened for their ability to recognise self-antigens. Cells bearing autoreactive receptors
are either eliminated by apoptosis (Nemazee and Burki, 1989) or are forced to modify
their BCR specificity by secondary rearrangements of their IgL loci (Gay et al., 1993;
Tiegs, Russell and Nemazee, 1993). This process is known as receptor editing and has
been well characterised for the Igκ  locus (Pelanda et al.,1997) but has also been
observed in the IgH locus (Taki et al., 1995) (Kleinfield et al., 1986). Receptor editing
involves a new recombination event, which removes the pre-rearranged VκJκ element
and leads to the assembly of a different variable region (Tiegs et al, 1993).
Figure 5:Receptor revision in IgL and IgH loci
More surprising however was the idea that RAG proteins might be involved in antigen
receptor diversification also later, in mature B cells, during an immune response. The
finding that RAG transcripts and protein can be detected in germinal centre B cells, or
upon activation of B cells in culture (Han, 1996; Hikida, 1996; Hikida, 1997), gave rise
to the provocative idea that the RAG recombinase could also be involved in affinity
maturation through a process called receptor revision (Kouskoff et al.,2000;Papavasiliou
- 12 -
et al., 1997). This can be easily envisaged as happening in the light chain locus, where
unrearranged VL and JL elements could be brought together, deleting the preformed VLJL
joint in a process similar to receptor editing. But even in the heavy chain locus
VH→VHDHJH rearrangements have been reported, mediated by cryptic heptamers present
in some V elements (V gene replacement)(Figure5) (Kleinfield et al., 1986; Reth et al.,
1986)(Taki, 1995). Receptor revision could be beneficial in deleting rearranged joints
which have acquired a crippling mutation during the somatic hypermutation process and
which are unlikely to be rescued by a second mutation at the same spot.
The role of RAG proteins, however, in peripheral B cells remains controversial; there is
mounting evidence that the observed expression outside the bone marrow is due to
residual expression in immature B cells which have not yet downregulated the RAG
proteins rather than re-induction upon antibody challenge.
1.7 Aim of the thesis
Germinal centre and activated B cells have been shown to express RAG proteins.
Double strand breaks, suggesting ongoing V(D)J recombination, have been detected in
the Igκ loci of these cells. In order to assess the extent of V(D)J recombination in
peripheral B cells and its contribution in shaping the secondary antibody repertoire we
decided to generate a mouse strain in which B cells re-expressing the RAG proteins in
the periphery would be labelled. Cells could then be sorted and analysed for secondary
recombination.
One way to generate such an indicator mouse strain, is by inserting a reporter gene
which will only be activated after RAG mediated recombination in peripheral B cells.
There are two essential requirements for such an approach:
-the reporter gene will have to be continuously expressed after recombination has taken
place, in order to allow detection of the desired B cell population.
-only B cells expressing the RAG proteins in the periphery should become labelled.
RAG mediated inversion should not take place during bone marrow development of B
cells, despite expression of RAG proteins.
RAG proteins when expressed can mediate recombination of an artificial reporter
substrate; this would provide a stable marker for B cells having expressed the RAG
proteins. Additionally, recombination of the substrate would provide evidence that the
proteins are fully functional for V(D)J recombination. This recombination event
however, should not occur in the bone marrow. Limiting recombination to peripheral B
cells could be achieved by taking advantage of differential accessibility of various loci to
recombination.
This idea brought us to a second point of interest: correlation of RAG accessibility and
transcription. The possibility that a transcriptionally inactive locus would be inaccessible
for V(D)J recombination and would become accessible upon induction of transcription
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could be analysed in the reporter mice. In parallel, transcription and V(D)J accessibility
were analysed in two other systems:
-an inducible system for transcription; efficiency of recombination could be analysed in
a stably integrated substrate, before and after induction of transcription
-a mutant mouse strain harbouring a transcriptionally active gene in the IgH locus.
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2. Materials and Methods
2.1 Molecular Biology
Common methods in molecular biology were performed according to standard protocols
(Sambrook, Fritsch and Maniatis, 1989) unless otherwise stated.
For most cloning purposes heat shock competent XL-1 Blue bacteria were used.
Isolation of plasmid DNA was performed using an alkaline lysis method (Birnboim and
Doly, 1979) . For cleaner preparations of plasmid Qiagen columns (Qiagen, Hilden)
were used. Targeting vectors were additionally purified on a CsCl2 gradient before
transfection into ES cells.
All enzymes used for restriction digests and cloning purposes were from New England
Biolabs (NEB, Beverly, USA) unless otherwise stated.
DNA was recovered from agarose gel slices with QIAEXII gel extraction kit (Qiagen,
Hilden) according to the manufacturer’s instructions.
DNA fragments were sequenced with the TAQ Dye Deoxy Terminator Cycle
Sequencing Kit (Applied Biosystems) and analysed on an ABI377 sequencing machine.
Concentration of nucleic acids was determined by measuring absorption of the DNA
solution at 260nm (and 280 nm) in a spectrophotometer (Pharmacia). Concentration of
genomic DNA or purified fragments used as probes was determined by agarose gel
elecrophoresis and comparison of the intensity of the band with λHindIII ladder.
2.1.1 Polymerase Chain Reaction (PCR)
PCR was used to amplify fragments for cloning, to analyse RAG or Cre recombination
events, and to screen mice or ES cells for the presence of targeted alleles. Typically PCR
reactions were performed in a volume of 50 µl containing 25 pmol of each primer, 5U
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Thermus Aquaticus (Taq) DNA polymerase (Gibco-BRL), 200 µM dNTPs (Pharmacia),
1x PCR Buffer (10 mM Tris-Cl pH=8.3, 50 mM KCl) and MgCl2 (concentration ranging
from 1-2 mM). In PCR reactions designed to amplify fragments for cloning purposes a
1:1 mix of Taq (Gibco, BRL) and proof reading PFU (Stratagene) polymerase was used.
A list of primers used in PCR reactions is given in Table 1.
# Name Sequence
1. Ex14.5’ GAA TGT CAG TCA TGT ACA GTT GC
2. Tm2-3’ GGG CTG GCT TAC AAA TCA GAG G
3. Ex12.5’ GCG TAA ATG ATT CTA AAG GTC ATG G
4. Ex15.3’ CTG GAT TCC ATT TGT ATC TTC AGG
5. CD21(ATG) GGG GAT CCC GGG TGT GCA GCA G
6. CD21intr.5’ CAA GTT CTT TTC TCT GAT ATA TCA G
7. CD21intr.3’ TTA CAC TAG TCG ACA GAT TTA TCA CTC ACA ATA TCA CTC
8. VH81x-5’ GGC CAA GTC GAC TGG AGG TTT TAG TTT GAG CTC ACA GTA ACT
 TTT GCT CAT TGT GTG TCT TGC AC
9. VH81x-3’ GGC CGT GCA AGA CAC ACA ATG AGC AAA AGT TAC TGT GAG CTC
AAA CTA AAA CCT CCA GTC GAC TT
10. DFL16.1-5’ AAT TTC GAG GCT TTT TGT GAA GGG ATC TAC TAC TGT GTT TAT
TAC TAG
11. DFL16.1-3’ AAT TCT AGT AAT AAA CAC AGT AGT AGA TCC CTT CAC AAA AAG
CCT CGA
12. PROM 5’ CTA GTC ACC TGC AGT TGT GC
13. PROM 3’ ACA TCC CTG GTT TGT CCT CTA ACC
14. LoxP-5’ AAT TTC TAG AGG TAC CAT AAC TTC GTA TAG CAT ACA TTA
TACGAA GTT AT
15. LoxP-3’ AAT TATAAC TTC GTA TAA TGT ATG CTA TAC GAA GTT ATG GTA
CCT CTA GA
16. LoxP-Cµ 5’ AGC TAA TAA CTT CGT ATA GCA TAC ATT ATA CGA AGT TAT AAG
CTT CAA TTG
17. LoxP-Cµ 3’ AGC TCA ATT GAA GCT TAT AAC TTC GTA TAA TGT ATG CTA TAC
GAA GTT ATT
18. RSS-5’ ATC CTA GGA GGG TTT TTG TAC AGC CAG ACA GTG GAG TAC TAC
CAC TGT
GCA GGA AGC TTC AGT GTC GAC ACC TG
19. RSS-3’ GCG GCC GCA ATG GCG CGC CGC TAG CCA GTG TTT TTG TTC CAG
TCT GTA
GCA CTG TGC AGG TGT CGA CAC TGA AGC TTC CTG
20. GFP-5’ CAT CGA GCT GAA GGG CAT CGA C
21. GFP-3’ GTA CAG CTC GTC CAT GCC GAG AG
22. Cre8 CCC AGA AAT GCC AGA TTA CG
23. CD19c AAC CAG TCA ACA CCC TTC C
24. CD19d CCA GAC TAG ATA CAG ACC AG
25. glD42i-5’ TGT CAA GAC TCT CAC TGT AG
26. glD42i-3’ CCG TCA GCT TCT GCA GCA TG
27. Mx-CreF CAT GTG TCT TGG TGG GCT GAG
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28. Mx-CreR CGC ATA ACC AGT GAA ACA GCA T
29. JHT1 CAG TGA ATG ACA GAT GGA CCT CC
30. JHT2 GCA GAA GCC ACA ACC ATA CAT TC
31. JHT3 CAC AGT AAC TCG TTC TTC TCT GC
32. BAP31 CTGTAGTCCACTGCAAACTCATC
33. CD21ex2fr
.
TGCTAAACCTTCTATTGTGAGTGA
34. oligo top TGCTAAACCTTCTATTGTGAGTGATATTGTGAGTGATAAATCTGTCGACT
GGAGGTTTTAGTTTGAGCTCACAGTAACTTTTGCTCATTGTGTCACAGT
35. oligo
bottom
CTGTAGTCCACTGCAAACTCATCCCGAAGGGGTTCGAATTTCGAGGCTT
TTTGTGAAGGGATCTACTACTGTGACACAATGAGCAAAAGTTACTGTGA
GCTCA
Table 1: List of primers used in PCR reactions and for cloning purposes
2.1.2 DNA preparation from mouse tissues and ES cells
DNA was prepared form mouse tissues and cells by incubation in Laird-Jaenisch (LJ)
lysis buffer (100 mM Tris-Cl pH=8.5, 5 mM EDTA, 0.2% SDS, 200 mM NaCl)
supplemented with proteinase K (1 mg/ml). Tissues/cells were incubated overnight at 55
°C and undissolved debris was pelleted by centrifugation. DNA was precipitated by
addition of equal volume of isopropanol, washed with 70% ethanol, airdried and
dissolved in 0.3x TE (Tris-EDTA, pH=8).
Genomic DNA from ES cells was prepared by directly lysing the cells in 96-well plates
according to the protocol by Pasparakis et al [Pasparakis, 1995 #5]. 50 µl of lysis buffer
(10 mM Tris-HCl pH=8, 10 mM EDTA, 150 mM NaCl, 0.2% SDS and 400 µg/ml
Proteinase K) were added to each well and plates were incubated overnight at 55 °C in a
humidified chamber. DNA was precipitated with 100 µl of EtOH, and subsequently
washed 3x with 70% EtOH. Plates were air dried and restriction digest mix was added
directly to each well.
2.1.3 Southern blot analysis
For southern blot analysis 5-15 µg of genomic DNA were digested with appropriate
enzymes at 37° C overnight. ES cell DNA was directly digested in the 96-well plate by
addition of 35 µl of restriction enzyme mix (20u enzyme, 1x restriction buffer, 100
µgr/ml BSA, 1 mM spermidine, 50 µg/ml RNAse and 1mM DTT) in each well and
overnight incubation at 37 ° C
Digested DNA was run on a 0.8% agarose gel, and blotted on a nylon membrane
(Hybond N+, Amersham) by dry capillary transfer. Membranes were baked at 80° C for
2 hours, pre-incubated in hybridisation buffer (1% BSA, 1mM EDTA, 0.5M Na-
phosphate pH=7.2, 7% SDS) for 1 hour and hybridised overnight at 65 °C. Probes were
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radioactively labelled with 32PdGTP (Amersham) using a random primer labelling kit
(Gibco). Unincorporated nucleotides were removed by centrifugation on a Sepharose
spin column (Pharmacia). After hybridisation membranes were washed four times for 20
minutes in wash buffer (1mM EDTA, 40 mM Na-phosphate pH=7.2,1% SDS) and
exposed overnight on autoradiographic films. More stringent washing conditions had to
be used for southern blot hybridisation when using the D probes (and specifically the
DFL16 probe) because of high unspecific binding. In this case blots were washed once
with 1%SDS 1x SSC, twice with1%SDS 0.5x SSC and once with 1% SDS 0.2xSSC at
65 °C. Blots were measured with a Geiger counter and if counts were high they were
washed further with 1% SDS 0.2x SSC.
The following probes were used:
-CD21 targeting: the 3’ external probe was a SacI-KpnI fragment form pBS-Cr2.5 (M.
Alimzhanov), which corresponds to Exon4 of the CD21 gene
-GFP probe (NheI-XhoI fragment from EGFP-C1)
-neor probe (XhoI fragment from plasmid neoflox-8)
-Cµ targeting: the 5’ external probe was 0.7 kb EcoRI-HindIII fragment from pBR322-
Cµ (RH probe)
-DQ52 probe: 1.2 kb XhoI-HindIII fragment from pDQ52
-DFL16 probe: 1.5 kb NsiI-BstEII fragment from plasmid pDFL3.8
All probes were gel purified after restriction digest of the respective plasmids.
Concentration of the purified probe was estimated by agarose gel electrophoresis and
50ng were used for the labelling reaction.
2.1.4 RNA preparation and competitive RT-PCR
RNA was prepared from sorted B and T cells using an RNA extraction kit (RNAeasy,
Qiagen). RNA was prepared from 105  cells and dissolved in 40 µl of DEPC treated
water. 10 µl of the RNA preparation were used for the cDNA synthesis reaction using
reverse transcriptase (Gibco). For the PCR amplification reaction 1.5 µl of the
synthesised cDNA was used. Different combinations of intron spanning primers for the
CD21 gene were tested on mRNA from total spleen and two primer pairs were selected
for further analysis (primers #1-4). The competitor molecule was generated by PCR
amplification of a 600 bp fragment from the CD21 transcript (primers #1, #2),
subcloning of this into pBS (using a Topo-TA cloning kit, Invitrogen) and removal of a
150 bp fragment from the middle by restriction digest with BstEII-HincII. The plasmid
was religated and removal of the 150 bp fragment was verified by restriction digest. The
concentration of the ‘competitor molecule’ was measured with a spectrophotometer, and
the number of molecules included in each reaction (x) was calculated from the measured
concentration (x= c[mol/l]*V[l]*N [1/mol], where x number of molecules, c;
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concentration [mol/l], V volume of competitor solution included in each reaction and N
Avogadro’s constant). Known amounts of this plasmid were included in the PCR
amplification reaction in order to quantitate the expression of CD21 in different sorted
cell populations. Actin primers were used as a control for the presence and the quality of
the cDNA template.
Another approach was also used, which involved direct cDNA synthesis from a small
number of sorted cells, without prior RNA purification. In this case 40 cells from the
different populations were sorted in tubes containing 10 µl of Buffer X (1x Superscript
Buffer, 10 mM DTT, 0.5% NP-40, 10 u RNA guard and 5s rRNA).  After sorting, 9 µl
of 1x first strand buffer (10 pMol oligo-dT, 5 mM dNTPS,) were added to each tube and
samples were incubated at 65 °C for 3 minutes. 1 µl of reverse transcriptase (1000 U/µl)
was added to each tube after cooling down and the reaction was then done according to
standard protocols. 1.5 µl of the synthesised cDNA was used for the PCR amplification
reaction.
2.1.5 Cloning of targeting vectors
Generation of targeting vectors and other plasmids is described below. Some cloning
intermediates and the final constructs generated are shown in Figure 6.
CD21 targeting construct
To generate the CD21 targeting construct a BamHI-HindIII 3kb fragment, containing the
first half of intron I was subcloned from pBSKSCr2HindIII (kind gift from Dr. Molina)
into the respective sites of pBSKS+ (Stratagene) (plasmid#1). The upstream XbaI-
BamHI fragment was also subcloned from the same plasmid into pBSKS and used as a
template for PCR mutagenesis of the first ATG of Exon1 (intoducing a SmaI site in
place of the ATG using primer#5 and T7)). The PCR product was blunted by Klenow
treatment, digested with NotI-BamHI and subcloned into the NotI-BamHI digested
plasmid#1. The resulting plasmid (plasmid#2) was sequenced to verify that no mutations
were introduced  by the PCR amplification. The second half of intron 1 was PCR
amplified (primer#6-#7) from a BAC-Cr2 clone (kind gift of Dr. Molina) in order to
introduce a SalI site into Exon 2. The resulting PCR product was blunted by Klenow
treatment, digested with HindIII-SalI and cloned into plasmid#2 (plasmid#3).
Plasmid Neoflox-8 (generated by M. Kraus) was modified by partial digest with XhoI
followed by Klenow treatment and religation. Plasmids where the downstream XhoI site
was destroyed were then selected. This neoflox-8(XhoI) plasmid was cut with NotI and
an RSS containing linker (VH81x-oligos #8,9) was inserted destroying the NotI site.
Sequence and orientation of the linker was verified by sequencing (plasmid#4).
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The GFP cassette was generated by cloning an RSS containing linker (DFL16.1-oligos
#10,11) into the EcoRI site of p31HR123-EGFPII (gift of S. Kuppig/ M. Reth) leaving
only one EcoRI site 5’ of the GFP gene. Sequence and orientation of the linker were
verified by sequencing (plasmid #5). In the remaining EcoRI site a LoxP-XbaI-KpnI
containing linker (oligos #12,13) was cloned. Sequence and orientation of the linker
were verified by sequencing (plasmid#6).The GFP-RSS-LoxP fragment was cut out
from plasmid#6 by XbaI-XhoI digest and cloned into the XbaI-XhoI site of plasmid#4
(plasmid #7).
The final construct (plasmid#8) for the targeting of the CD21 locus was generated by
isolating the GFP-neoflox cassete from plasmid #7 by SalI-KpnI digest and inserting it
into the SalI-KpnI site of plasmid#3. The short arm of homology (EcoRI-XbaI 1kb
fragment from pBSCr2.5) was then inserted in the KpnI site of this plasmid by blunt end
cloning.
Conditional Cµm targeting construct
The Cµm targeting construct was generated by subcloning an EcoRV-HindIII fragment
from plasmid pBR322-Cµ into the respective site of pBSKS (plasmid#9). Plasmid #9
was digested with HindIII and a LoxP containing linker (oligos #10,11) was inserted
downstream of Cµ membrane exons1 and 2. The sequence and orientation of the linker
was verified by sequencing. A second LoxP site was then inserted in the upstream
EcoRV site using the same linker which was blunted by Klenow treatment. Sequence
and orientation of the plasmid was verified by sequencing (plasmid #10). An FRT
flanked neomycin gene (1.4 Kb SalI-XhoI fragment from plasmid pGEM-FRT2neo,
generated by Ralf Kühn) was inserted by blunt end cloning in the EcoRI site of plasmid
#10 (plasmid #11). The long arm of homology, a 3 kb XbaI-EcoRV fragment from
pBR322-Cµ was blunted by Klenow and inserted in the SmaI site of plasmid #11. To
generate the targeting construct the short arm of homology was cloned in the HindIII-
MfeI sites of plasmid #11 as a HindIII-EcoRI fragment (from pBR322-Cµ) (plasmid
#12).
Tet-RSS construct
The Tetracycline Responsive Element (TRE) was subcloned from pTRE (Clontech) into
the XbaI-XhoI sites of pBSKS (plasmid #13). A double RSS containing linker (oligos
#12,13) was inserted in the XbaI site of plasmid #13. Sequence and orientation of the
linker were verified by sequencing (plasmid #14). The puromycin acetyltransferase gene
was cut out of the pGK-puroCre vector (A. di Nardo) with HindIII-XhoI and cloned into
the HindIII-SalI sites of plasmid #14 (plasmid#15). The last step was cloning GFP
(NotI-XbaI fragment from EGFP-C1, Clontech) into the AscI-NheI sites of plasmid #15
(plasmid #16).
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Figure 6: Cloning intermediates and targeting constructs generated. All constructs were cloned
using pBSKS as vector (indicated by jagged lines). Maps are drawn to scale except for loxP and
FRT sites and RSS.The sequence of the RSS inserted in the CD21 targeting construct is indicted
below the respective plasmids. Transcription is indicated by arrows under the gene and from the
respective promoters. Restriction digest sites: B; BamHI, E; EcoRI, EV; EcoRV, H; HindIII, K;
KpnI, M; MfeI, Nh; NheI, S; SalI, Sma; SmaI, X; XhoI, Xb; XbaI
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2.1.6 Transfections of 294 Cre and Flp expressing bacteria
To test the functionality of the loxP and FRT sites used in the targeting constructs
plasmids were transfected in 294 bacteria constitutively expressing Cre or FLP
recombinase (Buchholz, Angrand and Stewart, 1996). Transfections were typically done
by electroporation at 1.8 KV and 25 µF, bacteria were allowed to recover for 1 h at 37
°C and then plated on LB plates. Overnight cultures were grown from single colonies.
In the case of the CD21 targeting construct however, due to the presence of two inverted
loxP sites a different protocol was used. Growing bacteria at 37 °C resulted in aberrant
deletion of the intervening DNA due to high levels of Cre expression. Therefore bacteria
were transformed by mild heatshock at 37 °C for 5 minutes and then allowed to recover
at 30°C. Thereafter bacteria were grown at room temperature (RT) to ensure low Cre
expression.
Transformation of the 294-Cre bacteria was used to modify the CD21 targeting construct
(plasmid #). Following the mild transformation protocol single colonies were picked and
minipreps grown at 30 °C. All colonies had deleted the loxP flanked neomycin gene and
had either inverted (plasmid #18) or not inverted (plasmid #17) the GFP cassette. In
these plasmids the CMV promoter from pEGFP-N1 (MfeI-NotI fragment) was cloned as
a blunt end fragment in the SmaI site of exon1.
2.2 Cell culture and transfections
All tissue culture reagents used were purchased from Gibco-BRL unless otherwise
stated.
2.2.1 ES cell culture
Two different embryonic stem (ES) cell lines (Bruce-4 of C57BL/6 origin (Kontgen et
al., 1993) and IB10, a subclone of E14.1 ES cell line, of 129 origin (Kuhn, Rajewsky
and Muller, 1991) were used for generation of mice. ES cells were handled according to
protocols described elsewhere (Pasparakis and Kollias, 1995;Torres and Kuhn, 1997).
Cells were grown in DMEM media with 10% heat inactivated FCS (PAN Cat#3302-
P9795 Lot#P979549 for Bruce-4 cells and Gibco Cat#16141-079 Lot#34N4764 for
IB10), 2mM L-glutamine, 1mM sodium pyruvate, 1x non-essential aminoacids, 0.1 mM
β-mercaptoethanol and 103 u/ml LIF (leukemia inhibitory factor, Chemicon) on a
confluent embryonic fibroblast monolayer. Embryonic fibroblasts (EF) were mitotically
inactivated with mitomycin C (mmC, Sigma) (10 µg/ml for 2-3 hours) and rigorously
washed to remove traces of mmC before plating ES cells. ES cells were always split
before reaching confluence by mild trypsinisation (in the case of Bruce-4 cells trypsin
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was supplemented with 2% chicken serum). ES cell transfections were carried out by
electroporation using 30 µgr of DNA/107 cells in 0.8 ml of transfection buffer (20 mM
Hepes, 137 mM NaCl, 5mM KCl, 0.7mM Na2HPO4, 6mM glucose and 0.1mM 2-β-ME)
at 240 Volt and 500 µF (Biorad, GenepulserII). DNA was linearised before transfection.
ES cells were selected after electroporation with G418 (160 µg/ml active concentration
for Bruce-4 ES cells and 200 µg/ml for IB10 cells) and clones were picked 8 to 9 days
after transfection  and expanded directly into 96-well plates (Pasparakis and Kollias,
1995). ES cell clones were also frozen directly in the plates: 50 µl of trypsin were added
per well and incubated at 37°C for 5 minutes. Subsequently 50 µl of 2x freezing media
(FCS with 20% DMSO) were added and wells were overlaid with 100 µl of sterile light
mineral oil (Sigma). Plates were there frozen at –80 °C until homologous recombinants
were identified.
Specific deletion of the loxP flanked neor gene was performed by transient transfection
of Cre expression plasmid PGK-puro-Cre (A. di Nardo) in ES cells. Transfection
conditions are identical as described for the initial transfection. 5 hours after transfection
puromycin was added to the ES cell media (final concentration 1.25 mg/ml). Media was
changed to non selective media 24-36 hours later and cells were split and replated at a
density of 2 x103 cells per 10 cm dish on a fresh feeder monolayer. Clones were picked
6-7 days later, and analysed for G418 sensitivity.
2.2.2 B cell culture
B cells were isolated from the spleen and bone marrow of mice. Bone marrow was
flushed out from the tibia and femurs using a 24-G needle and spleens were removed,
ground to a single cell suspension between glass slides and washed in DMEM, 1% FCS.
Erythrocytes were removed by incubating the cells for 3 minutes in Red Blood Lysis
buffer (150mM NH4Cl , KHCO3, 0.1 mM Na2EDTA pH=7.2) at room temperature. To
remove monocytes and granulocytes a Ficoll (Pharmacia, Sweden) gradient
centrifugation was performed (2000 rpm, for 20 minutes at RT) and lymphocytes were
collected from the interphase. Macrophages were depleted by pre-plating the cells and
allowing them to adhere to plastic for 45 minutes; non adherent cells were harvested.
Cells were cultured in DMEM, 5% FCS, 0.1 mM 2 β-mercaptoethanol, 1x penicillin-
streptomycin, 2mM L-glutamine. For the LPS activation 20 µgr/ml of LPS (Sigma) was
added to the media while 100 U/ml of IL-4 were used. Initially 106 cells/ml were plated
in a 25 cm2 flask.
For the culture of bone marrow cells stromal cells (ST2 cells; Ogawa, 1988) were pre-
plated in the flasks and treated with mitomycinC for 4 h.
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2.2.3 Handling of HeLa and 293 Cells
HeLa Tet-ON cells were purchased from Clontech and used for all HeLa transfections.
Cells were cultured according to the company’s instructions (DMEM supplemented with
10% FCS, 4 mM L-glutamine, 1x Penicillin-Streptomycin, 100 µgr/ml G418).
Transfections were done using Lipofectamine 2000 (Gibco) according to the
manufacturer’s instructions. For the generation of stable cell lines with the Tet-RSS
construct (linearised with NotI) cells were treated with doxycycline containing media
(2µg/ml) after transfection. 24 hours later puromycin was added (1 mg/ml) for 48 hours.
Selection media was subsequently removed and cells were grown in the presence of
doxyxcyclyine until clones were large enough for picking. Cells were then kept in
doxycycline containing media supplemented with 500 µg/ml of puromycin.
For the transfection experiment, with the RAG expression vectors, cells were grown in 3
wells of a 6-well plate. In one case doxycycline free media was added, while in the other
two wells cells were grown in the presence of doxycycline. Cells were transfected with
RAG expression vectors and 48 hours later fresh doxycycline containing media was
added to all wells. Cells were trypsinised 24-48 hours later and analysed by flow
cytometry. 293 cells (Senapathy and Carter, 1984) were grown in in DMEM
supplemented with 10% FCS. Cells were transfected with lipofectamine 2000 (Gibco).
2.3 Immunostainings
2.3.1 FACS analysis
Staining of cells for flow cytometry were performed as previously described. The list of
antibodies used for different stainings is given in
Table 2. Antibodies were conjugated to FITC, PE, APC, CyChrome or Biotin.
Biotinylated antibodies were visualized with Streptavidin conjugated CyChrome.
Stained cells were analysed with a FACSCalibur (Becton Dickinson) and sortings were
performed with a FACStar (Becton Dickinson). For the exclusion of dead cells
propidium iodide (PI, 02µg/ml, Sigma) was added to the cell suspension just prior to
acquisition.
The list of antibodies used is given in Table 2.
Ab Name
(Clone)
Specificity Reference or supplier
RS3.1 IgMa (Schuppel, Wilke and Weiler, 1987)
MB86 IgMb (Nishikawa et al., 1986)
R33-24.12 IgM (Grutzmann, 1981)
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RA3-6B2 B220 (CD45R) (Coffman and Weissman, 1983)
S7 CD43 (Gulley et al., 1988)
1.3-5 IgD (Roes, Muller and Rajewsky, 1995)
7G6 CD21/CD35 Pharmingen (Heyman, Wiersma and Kinoshita,
1990;Wiersma, Kinoshita and Heyman, 1991)
8C12 CD21/CD35 Pharmingen (Heyman, Wiersma and Kinoshita,
1990;Wiersma, Kinoshita and Heyman, 1991)
AF6-120.1 MHCII (I-Ab) Pharmingen (Wall et al., 1983)
6D5 CD19 SBA,Inc
PNA lectin (Bramwell et al., 1982)
goat polyclonal IgG1 Southern Biotechnology associates (SBA)
B1-8µ NP (Reth, 1981)
267.7 NP (Reth, 1981)
1D3 CD19 (Krop et al., 1996)
Table 2: List of antibodies used for immunostainings and Elisa
2.3.2 Microscope slide stainings
In order to stain cells for microscopy, glass coverslips were washed with 70% EtOH,
then water and allowed to air dry. Coverslips were then coated with poly-L-lysine (0.1%
in water, Sigma) for 1 h and washed with PBS. Cells were resuspended in DMEM and
allowed to adhere to the glass slides for 30 minutes at room temperature. Cells were then
washed 1x with PBS and fixed with paraformaldehyde (2% in PBS) for 30 minutes at
RT. For intracellular staining cells were permeabilized with 0.1% Triton X-100 in
paraformaldehyde, washed 3x with PBT-glycine (PBS, 0.05% Tween 20, 50 mM
glycine) and blocked for 1 hour at room temperature with PBT-Block (PBS, 0.05%
Tween 20, 2% BSA, 0.05% gelatin and 50 mM glycine). Cells were incubated with
primary antibody (for FITC coupled antibodies 1:50 dilution was used, while
biotinylated antibodies were used at a dilution of 1:200 in PBT-Block) for 45 minutes at
RT. Cells were then washed 6x5 minutes with PBT and the secondary reagent was added
(strepatividin-TRITC, dilution 1:200 in PBT-Block) for 30 minutes at RT. Coverslips
were washed again (6x5 minutes with PBT), rinsed briefly with water and mounted on
glass slides with gelvatol.
Slides were stored at 4 °C and analysed with a Leica DM RXA microscope equipped
with epifluorescence.
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2.3.3 Magnetic cell sorting
Magnetic cell enrichment or depletion was done using MACS magnets and columns
according to the manufacturer’s instructions (Miltenyi Biotech, Bergisch Gladbach).
Cells were sorted by positive selection using directly coupled αB220 MACS microbeads
and αIgDbiotin-streptavidin-microbeads (10 µl of bead suspension in 90 µl
PBS/BSA/NaN3 for 10
7 cells). The purity of the sorted cell populations was tested by
FACS analysis using either an αB220 or an αCD19 antibody.
2.3.4 ELISA
Ig serum concentrations were determined by enzyme-linked immunosorbent
assays.(ELISA) as described by . Flat bottom microtiter plates (Costar) were coated with
50 µl antibody in PBS overnight at 4 °C. Plates were washed 3 x 5minutes with
PBS/0.1% Tween-20 (Sigma). Remaining binding sites were saturated by incubating the
plates with PBS/0.5% BSA for 2 hours at 37 °C. Plates were washed 3 x 5minutes with
PBS/Tween-20. Serially diluted serum samples were added to the wells (sera were pre-
diluted 1:50 in PBS) and incubated for 1 hour at 37 °C. Plates were washed and
secondary biotinylated antibody was added and incubated for 1 hour at 37. Detection of
the biotinylated antibody was achieved with streptavidin conjugated alkaline
phosphatase (AP, Boehringer) and p-nitrophenylphosphate (Boehringer) as a substrate.
The OD was measured with an Elisa photometer 30 minutes to 1 hour after addition of
the substrate at 405 nm.
2.4 Mice
All animals were kept in conventional mouse facility. Unless otherwise specified all
experiments were done with 8 to 12 week old mice.
2.4.1 Immunisation
Mice were immunised by intravenous injection (tail vein) of vesicular stomatitis virus
(VSV, 5x105 PFU Plaque Forming Units) or intraperitoneal injection of 4-hydroxy-3-
nitrophenylacetyl coupled chicken γ-globulin (NP-CG, 100 µgr/mouse in 200 µl of
PBS).
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2.4.2 Bone marrow transfer
Bone marrow cells were isolated from femurs and tibia of mice under sterile conditions.
Cells were resuspended in sterile PBS (without azide!) at a concentration of 107 cells/ml.
200 µl of the cell suspension were injected in the tail vein of sub-lethaly irradiated
RAG1/- mice. Host mice were irradiated with a X ray-source with a total dose of 600 rad
Antibiotics were administered in the drinking water of the animals one week before
irradiation and for an additional three weeks after reconstitution.
2.4.3 Typing protocols
The genotype of transgenic mice was determined by PCR. The CD21 targeting was
confirmed using internal GFP primers (oligos #20,21), the CD19-Cre transgenic line was
monitored using oligos #22-24, Mx-Cre with oligos 27-28, JHT with oligos #29-31 and
glD42Hi with oligos #25-26.
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3. Results
3.1 RAG expression reporter line
In order to assess the extent and significance of RAG re-expression in B cells after bone
marrow development a reporter mouse was generated. The idea was to label B cells that
express the RAG proteins after the bone marrow rearrangement programme has been
completed, and then isolate and analyse them for secondary V(D)J recombination in Ig
loci.
The reporter substrate was designed in such a way as to use the ability of the RAG
proteins to mediate DNA recombination. It contains a reporter gene, flanked by RSS,
which is inserted in the ‘wrong’ transcriptional orientation. RAG-mediated
recombination leads to inversion and expression of the reporter gene. The reporter gene
chosen was a variant of green fluorescent protein (GFP). However, it was necessary to
establish that RAG mediated recombination of the reporter substrate would not occur in
the bone marrow, when the RAG proteins are expressed for primary rearrangement of Ig
loci. In several systems (reviewed in Lewis, 1994) accessibility of a substrate for RAG
recombination correlates with transcriptional activation. Possibly, one way to exclude
recombination of the reporter substrate in developing B cells would be by introducing it
into a locus which is not transcribed in progenitor and precursor B cells, but becomes
transcriptionally active later.
The above criteria apply to the CD21 gene, which codes for complement receptors 1 and
2. The CD21 protein is expressed only on mature B cells and follicular dendritic cells
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(Kinoshita et al., 1988;Tedder, Clement and Cooper, 1984) which makes the CD21 locus
a potentially good candidate for introducing the RAG recombination reporter substrate.
3.1.1 Analysis of CD21 expression
Absence of transcription of the CD21 locus during bone marrow development (when
rearrangement of endogenous IgH and IgL loci takes place) is essential for preventing
rearrangement of the reporter substrate in progenitor and precursor B cells. Although it
has been reported that murine CD21 protein is expressed only on mature B cells, we
decided to perform a more extensive analysis of CD21 mRNA levels in different
populations of B cells from spleen and bone marrow.
Bone marrow fractions were identified according to cell surface markers (see Figure 2)
B220, IgM and CD43. Fractions A-C’ (pro-B cells), Fraction D (pre-B cells) and
Fractions E and F (immature and mature cells, respectively) from bone marrow were
sorted for analysis (Figure 7a). Immature (IgMhigh IgDlow) and mature (IgMlow IgDhigh) B
cells and non B cells (B220- cells which by forward-side scatter criteria would belong to
the lymphocyte population and are therefore designated as T cells in the subsequent
analysis) from spleen were sorted as positive and negative controls, respectively.
Another important consideration is the constitutive expression of the reporter gene in
germinal centre and post-germinal centre B cells. Since major differences in gene
expression profiles of these B cell subpopulations have been described, we decided to
check for CD21 expression levels in isotype switched cells (which are usually post
germinal centre B cells). For this reason IgG1 positive cells from immunised animals
were also sorted for CD21 mRNA quantitation (Figure 7b).
Figure 7: Sorting of B cells from a)Bone marrow: cells from Fractions A-C’, D, E and F were sorted
as indicated based on expression of B220, IgM and CD43. Cells from Fraction A-D are B220+, IgM-
and are further divided into Fractions A-C’ and D cells based on CD43 expression. Cells from
Fraction E are B220low IgM+ while those from Fraction F are B220high IgM+.
b) Spleen: Mature and immature cells were identified based on IgM, IgD expression; immature cells
are IgMhigh IgDlow while mature cells are IgMlow IgDhigh In the lower panel B220 negative cells
(designated as ‘T cells’) were sorted as negative controls, and memory B cells were identified as
IgG1+ cells (the plot is gated on B220+ cells).
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CD21 mRNA levels were analysed by RT-PCR. Initially RT-PCR was carried out on
cDNA prepared from crude lysate of cells sorted into a tube (40 cells/sample)(Figure
8a). Alternatively mRNA was prepared from sorted cells (105/sample) and then analysed
by competitive RT-PCR. Cells from the IgG1 population (which are representative of
the memory B cell pool) were only analysed by the direct RT-PCR protocol, since it was
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impossible to obtain enough cells for mRNA extraction and competitive RT-PCR
analysis. Two different pairs of intron spanning primers (Ex12.5’-Ex15.3’ and Ex14.5’-
Tm2.3’) were used for amplification. Actin transcripts were also amplified as internal
controls for determining sorting efficiency and monitoring the cDNA synthesis reaction
(Figure 8a). Additionally, expression of CD21 on germinal centre (GC) B cells was
monitored by staining spleen cells from immunised animals for CD21. Peanut agglutinin
(PNA) binding (Bramwellet al., 1982) was used to distinguish GC B cells (Figure 8b).
Figure 8: A) Analysis of CD21 expression levels by direct RT-PCR  (40 cells/reaction) of different
bone marrow fractions, and mature and immature B cells, B220- cells and IgG1+ cells from spleen.
Two different sets of primers, Ex14.5’-Tm2.3’ and Ex12.5’-Tm2.3’ were used. Actin mRNA was
amplified as a control for the cDNA synthesis reaction.
B) Expression of CD21 on germinal centre B cells. Splenocytes from immunised animals (day 13
post immunisation) were stained with αB220, αCD21 and PNA. The majority of PNA+ cells are
CD21+. The plot is gated on B220+ cells.
CD21 transcripts can be detected in immature, mature and IgG1+ cells from spleen but
not in T cells. Furthermore, most GC B cells (PNA+ cells) are CD21 positive. Bone
marrow fractions A to D do not have any detectable CD21 transcripts (while actin
mRNA can be amplified by RT-PCR from these samples). CD21 expression in Fraction
E is ambiguous; mRNA is amplified with one set of primers but not with the other.
Probably the two primer pairs have different efficiencies of amplification and if
expression is low only one PCR reaction is efficient enough to detect the CD21 mRNA.
B cells from Fraction F have detectable levels of CD21 transcripts with both primers
pairs.
In order to estimate the level of CD21 expression in the different B cell populations
competitive RT-PCR analysis was performed. The procedure relies on the co-
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amplification of the sequence of interest with a serially diluted, synthetic DNA fragment
of known concentration, using the same set of primers (Becker-Andre and Hahlbrock,
1989;Vu et al., 2000). The competitor molecule should give a distinguishable PCR
product from the endogenous gene. In this case, the competitor molecule was a fragment
of the CD21 cDNA, which was PCR amplified (using primers Ex14.5’ and Tm2.3’)
from total cDNA from spleen, and subcloned in pBSKS+. An internal 150 bp fragment
from this subcloned fragment was removed by restriction digest (HincII-BsteII) and the
plasmid was religated. Thus, a piece of DNA which is amplified with the same primer
pair but yields a shorter PCR product can compete with the CD21 cDNA for
amplification. Different amounts of competitor DNA were initially tested and thereafter,
different concentrations were used, so that amplification of the competitor DNA would
reflect expression levels of the endogenous gene. For bone marrow Fractions A to E ten-
fold serial dilutions (from 103 to 1 molecules) were included in each reaction, while for
Fraction F and splenic B cells twofold dilutions from 8*103 to 103 molecules were
analysed. The efficiency of mRNA isolation and cDNA synthesis from each sample was
verified by amplification of the actin transcript (data not shown).
Figure 9: Competitive RT PCR analysis of cDNA from different fractions of bone marrow and
splenic B cells and T cells. Primer pair Ex14.5’-Tm2.3’ was used. Different amounts of the
competitor molecule were included in each reaction as indicated below each lane. The upper band
results from amplification of the CD21 cDNA and the lower band from amplification of the
competitor molecule. The amount of CD21 mRNA in cells from each B cell fraction can be estimated
from the serial dilution of the competitor molecule in which the two bands are of equal intensity.
From the RT-PCR analysis of CD21 transcripts it appears that there is no detectable
transcription from the CD21 locus in bone marrow B cells from Fraction A to D (below
100 molecules/103 cells). CD21 transcripts appear in Fraction E, which corresponds to
immature B cells in the bone marrow and mRNA levels increase subsequently, with
highest expression in immature splenic B cells.
This analysis confirms the published reports about CD21 expression profile in B cells.
There is no detectable transcription in the early stages of bone marrow development
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while CD21 expression is strong in mature B cells, GC and post germinal centre B cells.
Therefore the CD21 locus seems suitable for insertion of the recombination substrate.
3.1.2 Generation of the CD21 targeting construct
In order to preserve the desired cell type specific and temporally regulated expression of
CD21 we decided to insert the recombination substrate into the CD21 locus by gene
targeting. Therefore a targeting vector for the CD21 locus was generated (see Figure 14).
This vector contains a neomycin resistance gene (neor) for selection in embryonic stem
(ES) cells, which is flanked by loxP sites and the GFP reporter gene flanked by
Recombination Signal Sequences (RSS). A modified version of the EGFP gene was used
(gift of S. Kuppig/M. Reth); this is an N-terminal fusion of EGFP (Clontech) with the
transmembrane region of BAP-31 (Adachi et al., 1996), which functions as an
endoplasmic reticulum (ER) anchoring signal. We chose to use this modified GFP
because it could be easier to localise in cryosections from spleen. A third loxP site is
located downstream of the GFP gene, in the opposite orientation in respect to the other
two; this loxP site was included in order to allow inversion the GFP gene by Cre
mediated recombination.
To avoid disruption of regulatory elements located in the promoter region and the first
intron, the neo-GFP cassette was inserted into exon 2 (disrupting the exon but retaining
the splice acceptor site) which is located 5 kb downstream of the first exon. The
initiation (cc)ATG(g) in the first exon was mutated to (cc)CGG(g) thus introducing an
analytical SmaI site for screening. Thus, after RAG mediated inversion (or Cre mediated
inversion) the first ATG for translation of the transcribed message will be that of the
GFP gene. 3 kb of genomic DNA (including the characterised 1.2 kb promoter region)
were included upstream of the ATG mutation as a long arm of homology (LAH) and
another 1 kb fragment was cloned downstream of the third loxP site as a short arm of
homology (SAH). Therefore, insertion of the GFP-neo cassette in the CD21 locus leads
to disruption of exon 2 and deletion of exon 3.
Before transfection in ES cells parts of the targeting construct were sequenced (promoter
region, coding region of genes and loxP and RSS sequences) and the functionality of
loxP sites and RSS sequences was analysed.
3.1.3 Cre recombination
In order to check the orientation and functionality of the loxP sites in the targeting vector
an intermediate plasmid generated during the cloning (plasmid #7), which contains the
neo-GFP cassette and the three loxP sites, was transfected in Cre expressing bacteria
(294-Cre; Buchholz et al., 1996) The two loxP sites (loxP1,2) flanking the neomycin
gene are in the same orientation and therefore Cre recombination should lead to deletion
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of this DNA segment. The third loxP site (loxP3), downstream of the GFP gene, is in the
opposite orientation and Cre recombination should lead to inversion of the GFP gene.
(Figure 10C). Plasmid #7 was transfected in 294-Cre bacteria and overnight cultures
were grown from single colonies. DNA was isolated from 10 overnight cultures and
digested with HindIII. Surprisingly, this yielded a 3kb fragment, which could only result
from complete deletion between loxP1 and loxP3 (Figure 10A). Sequencing the
recovered plasmids showed that in fact deletion had occurred, and only one loxP site
was left. The sequence of this loxP site was an overlap of the two inverted sequences
present in the parental plasmid.
Figure 10: A) Plasmid #7 before and after transformation in 294 Cre bacteria. DNA was isolated
from overnight cultures inocculated from single colonies and was digested with HindIII. DNA from
two colonies is shown B) Transformation of CD21final plasmid in 294 Cre bacteria. The bacteria
were grown at lower temperature; correct recombination events occur, as can be assessed by
digesting plasmid DNA with SalI-BamHI. In the minipreps from 294 bacteria both inverted and
not-inverted product is there (0.7 and 1.2 kb bands respectively) but subcloning  the plasmid gives
plasmids which have either inverted (#8) or not inverted (#10) the GFP gene. In all cases the
neomycin gene is excised C) Schematic representation of the DNA segment where recombination
takes place in both plasmid #7 and CD21 final. Diagnostic restriction digest sites are shown. The
length of the resulting fragments is not shown but the map is drawn to scale. Recombination
between loxP1 and loxP2 leads to deletion of the neomycin gene while recombination between loxP1
or 2 and loxP3 leads to inversion of the GFP gene.
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Sequencing again the plasmid showed that the three loxP sites were indeed in the
opposite orientation, but nevertheless deletion of the intervening DNA sequence occurs.
Further analysis of the phenomenon in collaboration with Dr. P. Droege (Aranda et al.,
2001) revealed that plasmids deleting one of the two inversely oriented loxP sites, which
can no longer serve as substrates for the inversion reaction, replicate at a higher rate,
diluting out both the parental and the correctly recombining plasmids. In this way,
aberrant recombination events, which can occur at as yet undetermined frequencies, are
selected. The phenomenon is dependent on high levels of Cre expression, possibly
because constant ‘flipping’ of the substrate hinders its replication and provides a
selective advantage for incorrectly recombined plasmids.
It was observed that when the 294-Cre bacteria were not grown at 37 °C, but at room
temperature (thereby reducing Cre expression levels) plasmids, which had correctly
recombined their loxP sites could be isolated. Plasmid yield was improved under these
conditions (Figure 10B). Since the inversion can take place in both directions, DNA
prepared directly from single colonies of the 294-Cre bacteria contains both possible
resulting plasmids: those, which have inverted the GFP gene and those, which have not.
These can be distinguished by BamHI-SalI digest, giving either a 0.7 kb or 1.2 kb
fragment respectively. Re-transforming the isolated plasmids in E.coli (not expressing
Cre) gives plasmids which have either inverted or not inverted the GFP gene (Figure
10B) .
From the above analysis it seems that the loxP sites inserted in the CD21 targeting
construct are in the right orientation and functional for Cre recombination.
3.1.4 RAG recombination
The RSS sequences introduced in the targeting construct are identical to those found in
the IgH locus adjacent to frequently recombining gene segments (VH81x and DFL16.1
specifically) and should therefore be functional in V(D)J recombination. Nevertheless,
we wanted to check the functionality of the RSSs in the targeting construct. To do so a
modified version had to be created. Modifications were necessary for two reasons; first,
expression of the reporter gene in the targeting construct is driven by the B cell specific
CD21 promoter, which is not expressed in most tissue culture cell lines and second, it
contains the neor gene. The neomycin gene has its own promoter and is positioned in the
opposite transcriptional orientation from the GFP gene potentially affecting expression
of the GFP reporter.
The control plasmid for RAG recombination was generated by transformation of the
CD21 targeting vector in 294-Cre expressing bacteria, and selection of clones with a
neor deletion but not GFP inversion. In this plasmid, the CMV promoter was inserted
into the SmaI site (which had been introduced in the ATG of exon 1) just in front of the
CD21 promoter (plasmid #17). A second control plasmid, introducing the CMV
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promoter in a plasmid, in which the GFP gene had been inverted by Cre, was also
generated (plasmid #18).
These two plasmids were transfected in HeLa and 293 cells together with RAG
expression vectors (RSV-RAG1 and RSV-RAG2 or CMV-RAG1 ands CMV-RAG2,
kind gift of G. Rathbun), or a Cre expression vector (PGK-puro-Cre, A. di Nardo). GFP
expression was visualised with a fluorescence microscope after transfection of cells (
Figure 11). GFP expression could be detected with both the inverted and the not inverted
plasmid.
Figure 11: 293 cells transfected with CMV(CD21) GFPinverted or CMV(CD21)GFPnot-inverted
plasmids (+RAG expression vectors) were visualised with a fluorescence microscope. GFP
expression could be detected in both cell lines
In a separate experiment cells were transfected with the plasmid #17 alone, or together
with PGK-Cre expression vector or CMV-RAG expression vectors and analysed by flow
cytometry for GFP expression (Figure 12). GFP expressing cells could be detected 72
hours post transfection but no such cells were present when plasmid #10 alone was
transfected into the cells. Only 0.4%-1.5% of cells are GFP positive possibly due to low
co-transfection efficiency, and the limited time available (in a transient transfection
experiment) for synthesis of recombinases, recombination and synthesis of the
recombined reporter to occur.
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Figure 12: FACS analysis of 293 transfected cells. Control cells were transfected with the plasmid
CMV(CD21)GFPnotinverted (plasmid #17). As a positive control plasmid #17 was cotransfected
with a Cre expression plasmid. In the last panel plasmid #17 was cotransfected with CMV-RAG
expression vectors. Cells were analysed 72 hours after transfection. GFP expressing cells can be
detected in both Cre and RAG contransfections but not in cells tranfected with plasmid #17 alone.
In order to verify that the cells observed with the FACS, had really inverted the GFP
gene, cells were sorted based on their GFP expression and PCR analysis was performed
(using primers BAP31 and CD21Ex2frw). Since there are not many cells expressing
GFP in these transient transfection experiments, different samples of 500 cells/tube were
sorted. From these cells it was impossible to obtain a clear PCR signal either from the
RAG or the Cre transfection experiment (Figure 13B). In fact, in an assay trying to
determine the sensitivity of the PCR reaction by titrating a synthetic oligo the detection
limit was approximately 5x103 molecules per reaction (Figure 13A).
Figure 13: PCR assay using primers BAP31-CD21Ex2frw and CD21inv5.2’-CD21inv3’. A) A
synthetic DNA oligo was used as a positive control for the reaction. The sensitivity of the reaction
was assessed by serial dilution of the synthetic oligo in cell lysate from 500 sorted 293 cells, starting
from 5x1011 molecules B) DNA from 500 transfected cells (with either plasmid #17+PGK-Cre or
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plasmid #17+CMV-RAGs) was PCR amplified with primers BAP31-CD21Ex2frw. A much better
PCR product was obtained using primers CD21inv5.2’-CD21inv3’ from DNA prepared from 104
sorted GFP+ 293 cells after transfection.
The transfection was therefore repeated and 104 cells were sorted from Cre and RAG
transfected 293 cells. DNA was isolated and a PCR product was amplified using a
different set of primers, CD21inv5.2’ and CD21inv3’ (Figure 13B).
The RSS can mediate RAG recombination and lead to inversion of the GFP reporter
gene in the context of plasmid DNA. The efficiency of the recombination seems lower
than that obtained with Cre, judging from the number of GFP+ cells in the Cre versus the
RAG transfection experiment (1.5% and 0.4% respectively). Of course this could also be
due to differences in transfection efficiencies, since in the case of RAG recombination
two expression plasmids have to be successfully co-transfected together with the
reporter plasmid while Cre recombination requires only one additional plasmid.
3.1.5 Targeting of the CD21 locus
After sequencing analysis and functional tests, the targeting vector for the insertion of
GFP recombination cassette in the CD21 locus was linearized with NotI and transfected
into ES cells (C57BL/6 derived Bruce-4 ES cells). After selection with G418 for 8 days,
400 neomycin resistant clones were picked, expanded and analysed by southern blot
hybridisation. The targeting construct, the genomic CD21 locus and the locus after
insertion of the substrate by homologous recombination are shown in Figure 14.
Figure 14: Targeting of the CD21 locus. The configurations of the targeting construct, the wildtype
locus and the targeted allele are shown. The arms of homology where recombination (indicated by
dashed lines) should occur are designated LAH (long arm of homology) and SAH (short arm of
homology). The map is shown to scale except for LoxP sites and RSS sequences. Restriction sites
used for screening are indicated: B, BamHI; S, SalI; H, HindIII . The external probe used to verify
the homologous recombination event and the expected sizes of the restriction fragments (in a
BamHI digest) are also indicated. PCR primers used forscreening are shown as arrows.
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Positive ES cell clones were identified by restriction digest either with BamHI or
HindIII and hybridisation with an external 3’ probe (Figure 15a). The mutation of the
ATG of the CD21 gene, introduced in exon 1, could not be verified by southern blot
analysis (SmaI digest of genomic DNA was incomplete). Co-integration of the mutation
was confirmed by PCR amplification of the first exon (using primers Prom5’ and
Prom3.2’) and restriction digest of the resulting PCR product with SmaI (Figure 15b).
Figure 15: a) Screening of ES cells for homologous recombination in the CD21 locus. Genomic DNA
from ES cell clones was digested either with BamHI or HinDIII and hybridised with a 3’ external
probe (see Figure 14). b) Co-integration of the mutation of the ATG in Exon 1 was verified by PCR
and restriction digest of the PCR product.
From the 400 colonies screened, 9 were positive for homologous recombination based
on the 3’ external probe (and verified by probing with a neomycin or a GFP probe).
Only two clones, 3-E9 and 4-B5, showed cointegration of the ATG mutation, as seen by
cleavage of the PCR product with SmaI.
The presence of the selection marker (which has its own thymidine kinase promoter) in
the CD21 locus might disturb the correct expression of the CD21 gene. Therefore
deletion of the neomycin resistance gene (neor) in ES cells, before generation of the
mice, was necessary. Since the neor  gene is flanked by two loxP sites it can be excised
by expression of Cre recombinase. Both homologous recombinant ES cell clones were
transiently transfected with a Cre expression plasmid (PGK-puro-Cre) and selected for
36 hours with puromycin (1.25µg/ml). Cells were grown for 8 days and 150 ES cell
colonies were picked from each transfection. Clones were analysed for G418 sensitivity
and expanded for southern blot analysis. Of the 300 picked clones (from both
transfections) 97 were G418 sensitive.
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Southern blot analysis was performed using a BamHI digest and part of the sequence of
GFP as a probe. Similarly to the analysis of the plasmid substrate for Cre recombination,
three recombination events are possible due to the presence of the third loxP site 3’ of
the GFP gene (Figure 14): deletion of the neor gene, deletion of the neor gene and
inversion of GFP, and only inversion of GFP without neor  deletion (Figure 16).
Figure 16: Cre-mediated recombination of the inserted substrate. A) Three possible recombination
events can occur (the first two are shown here); neor excision only, neor excision with concomitant
inversion of GFP and only inversion of GFP.  B) In the two first cases the recombination event can
be monitored by southern blot hybridisation following restriction digest of genomic DNA with
BamHI and hybridisation with a GFP probe. Neor clones give a 1kb band, neor deleted but not
inverted 7 kb fragment and neor deleted and inverted a 14 kb band
 Of the 97 G418 sensitive clones analysed 26 had deleted the neo r gene without having
inverted the GFP gene. In all other cases both deletion and inversion had taken place.
Blots were reprobed with a neomycin specific probe to verify excision of the neor (data
not shown). Two clones, which had deleted the neo gene and had not inverted the GFP
gene, 3E9-1B10 and 4B5-3C5 were injected into BALB/c blastocysts for the generation
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of chimeric mice. Germline transmission by coat colour was observed for two mice, only
one of which had the targeted allele.
3.1.6 Analysis of CD21 reporter mice
Some of the non-transmitting chimeras were used for analysis. In these mice ES cell
derived B cells can be discriminated from B cells derived from the blastocyst either by
allotypic differences of the IgM molecule (IgMb and IgMa respectively or of MHC
haplotype). Since RAG reactivation had been reported in germinal centre B cells, the
animals were immunised to induce germinal centre formation.
Initially one mouse (chimera 2993) was analysed, 13 days post immunisation with
Vesicular Stomatitis Virus. For FACS analysis, cells from spleen and bone marrow were
stained with an αIgMb antibody to be able to discriminate ES cell derived B cells
(IgMb+) in the chimera. B220 staining was used as a general B cell marker. In this first
analysis no FITC coupled antibody was used to allow detection of GFP expressing cells.
Splenic cells from immunised C57BL/6 mice were included as negative controls, while
as a positive control for GFP expression splenic cells from a GFP expressing transgenic
mouse (EBI-2, gift of S. Casola) were analysed.
- 43 -
Figure 17: A) FACS analysis of spleen of CD21 chimeras after immunisation. αIgMb staining was
used to distinguish ES cell derived B cells from WT BALB/c cells (from the injected blastocysts) and
B220 staining to identify B cells. Spleens from C57BL/6 mice were used as negative controls and
cells from EBI-2 mice as GFP expressing positive control. B) Histogram overlay of GFP intensity in
splenic cells from 2993 chimera and EBI-2 cells.
As can be seen in Figure 17A there is a small population of cells from the chimera which
show fluorescence in the GFP channel. These cells also appear in the WT control, but at
a much lower frequency (1% compared to 10% of IgMb or B220 positive cells).
However, the intensity of the GFP signal is much lower compared to the GFP expressing
cells from the EBI-2 mouse (histogram plot overlay in Figure 17B).
In order to confirm that the cells detected in the spleen of CD21-GFP RAG reporter
chimeras, represent GFP expressing cells that would result from RAG mediated
recombination, DNA from spleen, kidney and thymus of chimeric mice was prepared
and analysed by southern blot hybridisation (
Figure 18A). Inversion can be detected on the genomic level by southern blot analysis
using a BamHI digest and a GFP probe (as described for Cre recombination in ES
cells).The 14 kb band which would result from inversion of the GFP reporter gene
cannot be seen by the southern blot analysis. Therefore we designed a more sensitive
PCR assay, which would only amplify the inverted substrate (Primers CD21inv5.2’ and
CD21inv3’). DNA from ES cell clones in which inversion of the GFP reporter gene was
obtained by Cre mediated recombination was used as a positive control (Figure 18B).
Figure 18: Southern blot (A) and PCR analysis (B) of genomic DNA prepared from total spleen,
kindey and thymus of immunised chimera 2993. Southern blot hyibridisation was done using a
BamHI digest and a GFP probe, similar to the screening of Cre recombination in ES cells (see
Figure 16). RAG mediated inversion would give a 14 kb band similar to Cre mediated inversion.
The PCR was performed using primers CD21inv5.2’ and CD21inv3’ and genomic DNA from Cre
inverted ES cells as a positive control.
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The PCR analysis of splenic cells from this chimera also failed to detect the inverted
substrate. If the percentage of B cells that have undergone RAG mediated inversion is
very low, it is possible that the recombination event would be undetectable in DNA
prepared from splenic cells, even by PCR.
Therefore more chimeras were immunised (by intraperitoneal injection of NP-CG in
alum) and analysed 13 days later. FACS analysis of splenic B cells using αIgMb
antibodies as well as an antibody against an MHC class II molecule expressed on
C57BL/6 cells (MHC-II I-Ab) was carried out. Using this protocol of immunisation,
which was originally used when RAG proteins were detected in GC B cells, a small
population of ‘green’ cells could once more be detected in the chimeras. Also in this
case the intensity of the fluorescence was lower compared to the GFP expressing mice
used as positive control (data not shown). Bone marrow cells were also analysed by
FACS for GFP expression (Figure 19)
The reduced GFP expression in the CD21-GFP-RAG reporter mice could be due to the
use of the ER retained BAP31-GFP fusion, since it is known that resting B cells have a
restricted ER. LPS stimulation could overcome this limitation since it leads to activation
of B cells and formation of B cell blasts with an expanded ER network. Furthemore,
LPS in conjunction with IL-4 was described to induce RAG expression in peritoneal
cavity and mature B cells (Hikida et al., 1996; Qin et al., 1999).  For this reason splenic
cells from chimera 54006 were stimulated ex vivo with lipopolysacharide (LPS) and
interleukin-4 (IL4). However, no GFP expressing cells could be detected by FACS after
stimulation (Figure 19).
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Figure 19: Flow cytometric analysis of LPS stimulated splenic cells from chimera 54006 and a WT
C57BL/6 mouse. Cells were kept in culture with LPS+IL-4 for 4 days and stained with αB220. Cells
from bone marrow were also analysed by FACS for GFP expression.
We also decided to generate more animals by transfer of bone marrow cells from
chimeric mice into sub-lethaly irradiated RAG-/- hosts. All the lymphocytes in the host
mice eight weeks after the bone marrow transfer will be derived from the transferred
cells (Coligan, 1991). Different populations of cells were sorted from immunised bone
marrow chimeras and repeated the genomic analysis. The sorted fractions and number of
cells from each fraction are shown in Figure 14. All cells from spleen were sorted based
on the lack of MHCII I-Ad expression, which was used to exclude BALB/c derived cells.
Respective populations of splenic cells from immunised C57BL/6 animals were also
sorted.
Sample ID Description Number of cells
1 BM B220lowIgM+ 5x104
2 BM B220highIgM+ 5x104
3 B220+ IgD+ 2x106
4 B220+ PNA- 6x105
5 B220+PNA+ 2.7x105
Table 3: Sample identification and description of different populations of cells from immunised
CD21 chimeras sorted by FACS.
DNA was prepared from the sorted cells and analysed by PCR using the PCR assay
developed to detect inversion in 293 cells (see Figure 13). One tenth of the DNA from
each sorted fraction was included in the PCR reaction. As mentioned previously by
serial dilutions of the synthetic piece of DNA we were able to detect up to 5x103
molecules/reaction. However, mixing the synthetic oligo with genomic DNA from the
sorted cells further decreased the sensitivity of the reaction; in this case the PCR assay
using 5x103 molecules is not reproducible. Using this PCR assay we were not able to
detect RAG recombination in the different populations of sorted cells (Figure 20).
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Figure 20: PCR analysis of sorted cells from CD21 bone marrow chimeras. A,B) Synthetic oligo was
added in each reaction as a positive control to estimate the sensitivity of the PCR reaction, Two
different amounts were added, 5x104 and 5x103 molecules/reaction. The PCR signal in the second
case is not very robust. C) PCR analysis of sorted B cell fractions (1-5) and DNA from cells activated
in vitro with LPS, LPS+IL-4 and peritoneal cavity  (PC) B cells. Wild-type C57BL/6 DNA from
spleen was included as a negative control
No RAG mediated inversion in the chimeras analysed could be detected. Unfortunately
even by PCR we would be able to detect at best between 5x102 and 5x103 molecules per
reaction. Taking into consideration the amount of cells sorted from spleen, at least 5-
20% of the cells would have to have inverted the substrate to be detected by this PCR
assay and most of the cells from the bone marrow mature and immature fractions.
However, total DNA from spleen and thymus shows no detectable inversion.
3.2 Analysis of dependence of RAG mediated recombination and
transcription
The CD21-GFP RAG reporter mouse was generated to monitor RAG recombination in
mature B cells. In making this reporter mouse we relied on the inability of the RAG
proteins to recombine a substrate when it is inserted in a transcriptionally inactive locus.
Although there is evidence supporting this hypothesis in Ig and TCR loci (Lewis, 1994)
there is no direct system correlating induction of transcription and V(D)J recombination.
In order to address this question more directly we decided to use an inducible gene
expression system and monitor dependence of recombination on transcription. For this
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reason the tetracycline inducible promoter (Tetracycline Responsive Element) was used
(Gossen et al., 1995).
The recombination substrate generated is not identical to the one used for the CD21
targeting; in this construct a puromycin resistance gene is flanked by RSS sequences and
inserted downstream of the tetracycline responsive element (TRE). Expression of the
puromycinr gene can be induced by tetracyclines and provides a selection marker for
generation of stable lines. Additionally it functions as a translational stop cassette
(Angrand et al., 1998) preventing expression of the GFP reporter gene, which is located
downstream. RAG-mediated recombination leads to deletion of the puromycinr gene and
subsequent GFP expression (Figure 21).
Figure 21: Representation of the RAG recombination substrate generated for transfection in HeLa
Tet-On cells. The Tet Responsive Element drives transcription of a puromycin gene in the presence
of the inducer (doxycycline). The puromycin gene has a polyadenylation signal, which prevents
translation of the downstream GFP and is flanked by Recombination Signal Sequences (RSS). RAG
recombination leads to deletion of the puromycin gene and subsequent GFP expression.
The construct was linearised and transfected in HeLa Tet-On cells (Clontech) which
express the reverse teracycline-controlled transactivator (rtTA). Upon addition of
doxycycline genes driven by the Tet promoter are activated. The activation of expression
was assessed using a tet-luciferase construct (data not shown). After transfection cells
were selected with puromycin (1 µg/ml) in the presence of doxycycline (2 µg/ml) for 2
days. To reduce stringency of the selction cells were subsequently grown in 500 µg/ml
puromycin (and doxycycline) and when clones had reached a reasonable size were
picked for analysis. As expected, in the absence of RAG mediated recombination and
removal of the puromycinr gene no GFP expression was detected in these cells.
Only in three, of the 18 clones picked, GFP positive cells could be detected after
transfection with the RAG expression vectors. Two of these clones were analysed
further. Cells were grown in the presence or absence of doxycycline and transfected
either with RSV-RAG1,2 or LTR-RAG1,2 (LTR expression vectors were only used in
the presence of doxycycline). 48 hours after transfection all samples were treated with
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doxycycline containing media, to induce GFP expression and 36 hours later cells were
analysed by FACS (Figure 22).
Figure 22: FACS analysis of HeLa cells stably transfected with the recombination substrate and
selected for puromycin resistance. Two clones were analysed for GFP expression after transfection
with RAG expression vectors in the absence (left panels) or presence (middle and right panels) of
doxycycline.  The numbers on the upper right corner of each plot indicate percentage of GFP+ cells.
In clone #1 (top row) no GFP expressing cells were present when transfection with the
RAG expression vectors was performed in the absence of the transcriptional inducer. In
the presence of doxycycline 0.1% to 0.2% (depending on the RAG expression vector
used) of the cells expressed GFP. In contrast clone#2 (bottom row) showed a GFP
positive population irrespective of whether the transfection was performed in the
presence or absence of doxycycline. Overall the number of GFP positive cells in this
clone is much higher than that detected after transfection of Clone#1  (close to 1% with
doxycycline and 2.4% in the absence). Therefore transcription could be important for
activating RAG recombination but there is a variability in the process, probably due to
integration site of the recombination substrate.
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3.3 Analysis of allelic exclusion in µMT mice
Another phenomenon where locus accessibility for RAG recombination seems to play a
major role is allelic exclusion. Typically immunoglobulin heavy chain (IgH) loci stop
rearranging after successful assembly of a heavy chain. There are several mouse
mutants, where a breakdown of allelic exclusion has been described (Kitamura and
Rajewsky, 1992; Loffert et al., 1996). In most cases this is due to inability of pro-B cells
to present a functional pre-B cell receptor on their surface and therefore shut down
rearrangement on the other IgH allele. One such mouse model, is the µMT mouse,
which contains a neomycin gene disrupting the first membrane exon of IgM (Kitamura
et al., 1991). B cells with functional rearrangements on both IgH alleles can be detected
in heterozygous µMT mice and these cells are termed ‘double producers’. What is
surprising however is that the frequency of double producers in the bone marrow, is
higher than theoretically predicted (25% versus 12.5%, see Discussion 4.3). The
presence of the neomycinr gene, which has its own promoter, in the IgH locus could be
the reason for the observed discrepancy; a transcriptionally active gene could alter
accessibility of the locus to RAG recombination and lead to preferential rearrangement
of the neomycinr containing allele. Another idea is that the neomycinr gene could
prohibit establishment of allelic exclusion, and therefore this allele would go on
rearranging even after signalling through the pre-B cell receptor has been established.
 To test these two possibilities we decided to study the phenomenon in a context, which
promotes allelic exclusion. Therefore, the µMT mice were bred to a heavy chain
insertion mouse, which is a mouse in which a functional VHDHJH element has been
inserted by gene targeting into the IgH locus (Taki, Meiering and Rajewsky, 1993). In
such a mouse most B cells express the pre-rearranged heavy chain, since the inserted
VHDHJH gene in a heterozygous configuration prevents rearrangement of the other heavy
chain allele. The heavy chain insertion mouse we chose to use was glD42Hi (Pewzner-
Jung et al., 1998), because antibodies produced in this mouse strain can be distinguished
from antibodies generated from the µMT allele by allotypic differences (IgMa and IgMb
respectively). Anti-allotypic staining could be used to distinguish antibodies produced
from each allele, and thereby estimate the number of cells harbouring VHDHJH
rearrangements on both chromosomes.
Homozygous µMT mice were crossed to heterozygous glD42Hi. Since the
glD42Hi mutation is not bred on a specific genetic background, the µMT
mice were also crossed to BALB/c and C57BL/6 mice as controls.
The µMT mutation does not allow the expression of surface IgM (Kitamura et al., 1991),
so production of secreted antibody had to be detected. Therefore B cells from spleen and
bone marrow of µMT/glD42Hi, µMT/WTC57BL/6 and µMT/WTBALB/c a n d
glD42Hi/C57BL6 mice were cultured in the presence of lipopolysaccharide (LPS) to
stimulate antibody production. Cells were kept in culture for 4 days and subsequently
analysed for IgMa and IgMb production by intracellular staining. Only cells that have
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rearranged both IgH alleles (or in the case of the glD42 insertion mouse, the remaining
heavy chain allele) can produce antibodies of both allotypes. Splenic cells were analysed
either by FACS or allowed to adhere on glass slides, stained and counted under a
fluorescent microscope. Cells from bone marrow were only stained on microscope slides
since intracellular FACS staining was not reproducible, due to their high
autofluorescence. As can be seen from the FACS plots there are no detectable double
producers in the spleens of µMT/glD42Hi mice. Both IgMb+ cells or B220+ are not
IgMa+. In contrast, in the µMT/WTC57BL/6 splenic cultures, a distinct population of
double producers was observed (Figure 23).
Figure 23: FACS analysis of LPS activated splenic cells from glD42Hi/µMT, glD42Hi/WT, µMT/
WTC57BL/6 and µMT/WTBalbC .  A) In the upper panel IgMb
cychrome versus IgMaFITC staining is shown;
B) B220 versus IgMa staining. Most cells are B220+ but only 32% of the cells are stained for IgMa
even in the positive control (µMT/BALBc).
In the same experiment glD42/C57BL6 mice, which can only produce IgMb antibodies,
were included as negative controls, while the µMT/BALBc mice, which can only make
IgMa antibodies were used as positive controls. As can be seen from the FACS plots, the
glD42/µMT mice have background levels of IgMa+ cells (less than 1%). Surprisingly
only 32% of B220+ cells in the µMT/BALBc mice are IgMa+, probably due to efficiency
of the LPS activation and/or intracellular staining. In µMT/C57BL6 heterozygous mice
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1.94% of B220+ cells are IgMa positive, which assuming the same efficiency of
activation and staining as the positive control would correspond to 6.1% of double
producers. In the double staining with αIgMa and αIgMb (upper row) approximately 4%
of the IgMb+ cells are IgMa+.
Cells were also counted on slides after staining with α-IgMa and α-IgMb antibodies.
Figure 24: Antiallotypic staining of LPS activated bone marrow cells (upper two rows) and spleen
(lower two rows) from glD42Hi/µMT and µMT/ WTC57BL/6 mice. IgMa was detected with antibody
RS3.1 (green) and IgMb with MB86 (red). Double producers appear yellow in the last panels
(merged image).
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The number of double producers counted in µMT/C57BL6 mice, in three independent
experiments is between 4-7% in the spleen and ~20% in the bone marrow. On the other
hand glD42/µMT mice have less than 1% double stained cells in the spleen and ~2% in
the bone marrow. The results from FACS analysis and slide stainings are summarised in
Table 4.
Strain FACS stainings Slide stainings
B220+ IgMb+ Spleen Bone marrow
glD42/µMT 0.5% 0.1% 0.3%
(1/476)
2%
(2/110)
µMT/C57BL6 6.4% 4.2% 5.8%
(39/670)
22.2%
(48/216)
Table 4: Percentages of double producers from µMT/C57BL6 and glD42/µMT mice. In the FACS
stainings values were calculated either from B220 versus IgMa staining or IgMb-IgMa double
staining. The values given for the B220 staining were normalised for efficiency of the IgMa staining
as assessed from the µMT/BALBc positive control. (~30%). Cells on slides were stained for IgMa
and IgMb; the number of double positive versus single positive (IgMb+) cells counted is given in
parenthesis. Values are the means of two independent experiments.
Absence of double producers in the µMT/glD42 cross indicates that the inserted VHDHJH
allele efficiently blocks rearrangement of the neomycin containing allele.
Another way to directly assess the presence of double producing B cells in the mice is
by analysis of serum titers of unimmunised animals for IgMb and IgMa antibodies by
Elisa (Figure 25 and Figure 26 respectively).
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Figure 25: Determination of IgMb titers by an Elisa assay in glD42/µMT and µMT/C57 mice.
BALB/c and C57 animals were included as controls. As expected both µMT/C57 and glD42/µMT
produce comparable levels of IgMb antibodies.
IgMb titers from the mice were analysed to determine total IgM production
(IgMa+IgMb). As expected the titers for IgMb are similar in µMT/C57BL6, glD42/µMT
and C57BL/6 animals since all three mice can produce antibodies of the IgMb allotype,
while BALB/c mice show no detectable levels of IgMb. Measuring IgMa titers (Figure
26), which can be produced from the µMT allele, would give an indication for the
presence or absence of double producers.
Figure 26: ELISA assay to determine the IgMa serum titers of µMT/C57BL6 and glD42/µMT mice.
Sera from BALB/c and C57BL/6 mice were included as controls.
IgMa titers are very different; BALB/c mice which only express IgM antibodies of the a
allotype have approximately 300 µg/ml of IgMa antibodies in their sera, as estimated
from the titration curve, while µMT/C57BL6 mice have 20~10µg/ml. IgMa antibodies
were not detected in the serum of glD42/µMT mice, which supports the observation that
no double producers cells are present in the spleen of these mice.
Finally rearrangement of the IgH locus can be directly monitored at the genomic level
by southern blot analysis. Two probes DQ52 and DFL16 have been described which
bind to regions upstream of DQ52 (which is the last D element of the IgH locus) or
upstream of DFL16.1 (which is the 5’ most D element) respectively. Most  DH→JH
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rearrangements will lead to deletion of the region recognised by the DQ52 probe and
IgH allele, regardless if this is productive or non productive.
To assess the extent of rearrangement in µMT/C57BL6 compared to glD42/µMT mice
and wild-type mice, B220+ and B220- cells from spleen were isolated by magnetic cell
sorting (MACS). The purity of the populations after MACS purification was calculated
by immunostaining for CD19 and B220 and analysis by flow cytometry. In all cases the
purity of the B220+ cells was more than 90%. The percentage of contaminating B220+
cells in the B220- population was between 5 and 10% (data not shown).
Figure 27: A) Organisation of the 3’ region of the IgH locus and binding sites of the two probes used
for analysis, DQ52 and DFL16. DH→ JH rearrangement leads to deletion initially of the fragment
recognised by the DQ52 probe and VH→DHJH rearrangements of that recognised by the DFL16
probe. The DFL16 probe recognises two regions, upstream of DFL16.1 and DFL16.2 respectively B)
Southern blots from MACS purified B cells and non B cells (B220+ and B220- respectively) from
spleens of glD42/µMT mice, heterozygous µMT and wildtype mice. To estimate the amount of DNA
loaded per lane both blots were reprobed with the CD21 probe (lower panel).
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DNA was prepared from B220+ and B220- cells from wild-type, glD42/µMT and
µMT/C57BL6 mice. DNA was digested either with AccI or EcoRI and blots were
probed with DFL16 and DQ52 probes respectively. The DFL16 probe binds specifically
two DNA fragments, one located upstream of DFL16.1 (7.7 kb) and another upstream of
DFL16.2 (2.2 kb). Quantification of the amount of DNA loaded per sample was
performed by reprobing the blots with an unrelated genomic probe (either the CD21
probe or in the case of thymus DNA with DFL16 probe the Cµ RH probe was used as a
DNA loading control). The intensity of the bands on the southern blots was quantified
using Imagequant software and a STORM phosphoimager (Molecular Dynamics) and
re-analysed with a quantitation programme written by H. Stoffler. The results are shown
in Table 5 as the ratio of the signal of each D probe to the CD21 control probe.
STRAIN DQ52 DFL16.1 DFL16.2
glD42/µMT B220- 0.61 0.64 1.2
glD42/µMT B220+ 0.12 0.71 1.0
glD42/µMT Thymus 0.35 1.9 2.2
µMT/WT B220 - 0.57 0.72 1.1
µMT/WT B220+ 0 0.08-0.15 0.5
µMT/WT Thymus n.d 2.2 2.7
WT B220- 0.65 0.9 1.1
WT B220+ 0.02 0.4 0.67
WT Thymus n.d 2 2.2
Table 5: Intensity of the signal of DQ52 and DFL16 probes quantified by phosphoimager and
ImageQuant software. The numbers given represent the ratio of the intensity of the bands of either
the DQ52 or the DFL16 probe to the CD21 probe. For thymus DNA quantitation the RH probe was
used, which due to different binding efficiency compared to the CD21 probe gives a different ratio.
However the value is close to 2 in all three mouse strains, suggesting that no rearrangement takes
place in thymocytes in these mice.
The loss of the DQ52 probe signal is due to DH→JH rearrangement which is known to
happen in the majority of B cells on both alleles, and can also occur in T cells . In µMT
heterozygous mice as well as in WT mice the DQ52 probe signal is almost undetectable
in B220+ cells. In B220+ cells from the glD42/µMT mice the DQ52 signal from the
wild-type allele is reduced about fivefold (0.12/0.60), suggesting that DH→JH
rearrangement does occur. There is no reduction of the signal from the targeted allele
since all JH elements have been removed by the targeting and no DH→JH joining can
occur. Some loss of DQ52 signal also happens in the thymus of the gld42/µMT mice
(0.35/0.6) where DH→JH rearrangement is known to occur.
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Since IgH allelic exclusion is established as a block of VH →DHJH rearrangement,
analysis of DFL16 probe signal is more informative about the breakdown of allelic
exclusion. Southern blot hybridisation shows that there is no significant loss of DFL16
signal in the glD42/µMT mice (comparing B220+ and B220- cells from spleen)
suggesting that no significant VH →DHJH rearrangement happens in B cells in these
mice. No differences in DFL16 signal intensity are observed in thymus DNA from
glD42/µMT, µMT/WT and wild-type mice.
On the other hand µMT heterozygous mice and WT mice show a significant reduction in
the signal of the DFL16 probe in DNA from B220+ cells. The reduction is stronger in
µMT/WT mice supporting the finding that in these mice there is a higher number of
double producers (6-25% compared to 0.1% in wild-type mice (Barreto and Cumano,
2000). Loss of the signal of the DFL16 probe, especially of theDFL16.1 band, makes it
hard to quantify both in WT and especially in µMT heterozygous mice. The values in
individual experiments and using different quantitation software range from loss of up to
90% (suggesting almost complete rearrangement) to 70% of the DFL16.1 signal.
From the above analysis it appears that allelic exclusion in glD42/µMT mice is not
impaired. There are no detectable double producers after LPS stimulation and staining of
cells on slides or analysis by flow cytometry, and there are no detectable levels of IgMa
antibodies in the sera of these mice. Furthermore, the genomic locus doesn’t seem to
undergo VH →DHJH rearrangement although some DH→JH rearrangement does take
place. We conclude therefore that the high number of double producers in the µMT
heterozygous mice is due to preferential recombination of the targeted, neomycin
containing allele during recombination of the IgH locus, rather than rearrangement of
this allele during light chain rearrangement.
3.4 Conditional disruption of IgM membrane exons
As previously mentioned, in the µMT mouse (Kitamura et al., 1991) the first membrane
exon of the constant region of IgM is disrupted by insertion of a neomycin resistance
gene, which blocks the production of membrane bound IgM. The neomycinr gene has its
own promoter (thymidine kinase promoter) and is stably integrated in the genome. Since
it is impossible to remove this gene, it is difficult to assess the importance of an actively
transcribed gene in the Ig locus and analyse its significance independently of the
truncation of the IgM membrane region.
Therefore, we decided to generate a mouse strain (Cµ membraneflox) in which the
neomycinr gene is targeted in the constant region of IgM (similar to the situation in the
µMT mouse) but can later be removed by a genomic recombination event.
A targeting construct which has a neomycin resistance gene just upstream of the IgM
membrane exons was generated. The neomycinr gene is flanked by Flip Recombinase
Target (FRT) sites and can be removed by expression of Flp recombinase. The two
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membrane exons, on the other hand, are flanked by loxP sites and can be deleted by
expression of Cre recombinase.
The targeting construct was generated as described in Materials and Methods and
linearized with NotI. Bruce4 ES cells were transfected and selected for G418 resistance.
Clones were picked and analysed for homologous recombination by Southern blot
hybridization using an EcoRI digest and a 5’ EcoRI-HindIII fragment as a probe (RH
probe) (Figure 28).
Figure 28: A)Generation of homologous recombinant Cµ membraneflox ES cell clones. The
configurations of the targeting vector (top), the wild-type IgM constant region locus (middle) and
the targeted locus after homologous recombination (bottom) are shown. The external probe used for
screening is shown (open rectangle) as are the diagnostic fragments generated after an EcoRI digest.
Arrows underneath the targeting construct indicate the direction of transcription of the selection
marker gene. Short arm of homology (SAH) and long arm of homology (LAH) where homologous
recombination should take place are indicated by dashed lines. loxP sites are indicated as boxed
triangles and FRT sites as triangles. Restriction sites displayed: E, EcoRI; H, HindIII; X, XbaI; EV,
EcoRV
 From 300 clones picked no homologous recombinants were identified. The DNA used
for the generation of the targeting construct (long and short arm of homology) is
BALB/c derived and polymorphisms in the IgM genomic locus, could reduce the chance
of homologous recombination using C57BL/6 ES cells. Therefore the ES cell
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transfection was repeated with the same targeting construct but targeting 129 derived ES
cells (the subclone of the E14.1 ES cell line, IB10). 600 colonies were picked and
analysed by southern hybridization using the same probe and restriction digest as
previously described. Three homologous recombinants were identified. Co-integration
of the downstream loxP site was monitored by PCR. Only one of the three clones (4G6)
gave a positive PCR signal (Figure 29).
Figure 29: Southern blot analysis of ES cells using the 5’ EcoRI-HindII fragment as probe (RH
probe). ES cell DNA was digested with EcoRI which gives an 11 kb wild-type band and an 8 kb
band in case of homologous recombination. Samples are loaded in two levels which are misaligned
(lower band is wildtype band of clones H3,H4, etc. running 0.5 cm below the top lane).
The targeted clone was injected in C57BL/6 and CB20 blastocysts and chimeras were
generated. These are breeding for germline transmission with Flp-Deleter (Farley et al.,
2000) or CD19-Cre (Rickert, Roes and Rajewsky, 1997) or Mx-Cre (Kuhn et al., 1995)
mice, which have been crossed to JHT mice. The progeny will have one JHT allele
(which cannot code for immunoglobulin, since the J elements have been deleted) and the
targeted allele. Depending on the cross the neomycin gene will be deleted (in the case of
the Flp-Deleter cross) or the Cµ membrane exons will be removed by Cre recombination
early in B cell development (CD19-Cre) or later after induction of Cre transcription from
the Mx promoter. Therefore there is no need to breed homozygous mice,but the effect of
the mutation can be directly analysed in the progeny of the chimeras.
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4. Discussion
4.1 Recombination Activating Gene (RAG) protein expression in
peripheral B cells
Developing B lymphocytes express RAG proteins in order to assemble their Ig
receptors. The finding that RAG proteins can also be expressed in peripheral B cells,
either in germinal centres and or upon activation with LPS and IL-4, lead to speculation
about their possible involvement in the process of affinity maturation (Han et al.,
1996;Hikidaet al., 1996). RAG protein expression is not necessarily indicative of
ongoing V(D)J recombination, but double-stranded RSS breaks, characteristic of RAG
activity were additionally detected in the Igκ loci in splenic B cells in and ex vivo (Han
et al., 1997; Papavasiliou et al., 1997). Therefore a novel mechanism, involving V(D)J
recombination,  for generation of secondary antibody diversity was postulated.
Initially, such an idea might appear absurd, since the chances of ruining productively
rearranged elements, which can already bind antigen with certain affinity are high. The
process of affinity maturation however is ‘expensive’ and massive cell death occurs in
the germinal centre reaction (MacLennan, 1994). Receptor revision could be a
successful mechanism for the generation of antibody diversity considering that
antibodies with similar specificities have identical heavy and different light chains and
that VH and VL elements can be clustered into families with significant sequence
similarity (Kabat and Wu, 1991;Strohal et al., 1989). Therefore, replacement of the light
chain variable region, by de novo rearrangement, could result in subtle changes of BCR
specificity, comparable to those introduced by somatic hypermutation. It should be noted
that, recombination intermediates and RAG mRNA are reduced upon antigen receptor
engagement in mature B cells (Hertz et al., 1998) (Meffre et al., 1998), which is in
contrast to the situation in immature B cells of the bone marrow, where receptor editing
is stimulated or maintained by autoreactive receptors (Hertz and Nemazee, 1997). The
- 60 -
objective of receptor revision seems to be the generation of a BCR able to recognise
cognate antigen with higher affinity, upon which RAG expression is down-regulated.
Evidence that RAG1 is abundant in apoptotic B cells in the germinal centre (Hikida et
al., 1997), suggests that V(D)J recombination could also rescue cells that have acquired
a crippling mutation of the rearranged variable region during the process of somatic
hypermutation.
After the original observation of RAG expression in peripheral B cells, and in the course
of this work, several mouse models for monitoring RAG expression were generated;
these are very similar in that they contain a targeted insertion of a reporter gene (GFP)
either in the RAG-1 (Kuwata et al., 1999) or RAG-2 locus (Gartner et al., 2000). In
another mouse strain GFP is inserted as a BAC transgene using the RAG2 promoter (Yu
et al., 1999). B cells coming from the bone marrow, but also T cells in the thymus
express GFP, since the respective RAG promoters drive transcription of the reporter
gene in these populations. GFP expression decreases subsequently and there is no
apparent re-induction after immunisation. Culture of GFP- and GFP+ cells with LPS and
IL-4 does not lead to GFP expression or maintenance of the signal respectively.
Therefore, cells that express RAG proteins in the periphery and can potentially undergo
receptor revision seem to belong to a population of immature, transitional B cells
(Carsetti, Kohler and Lamers, 1995) whose emigration from the bone marrow is
facilitated by immunisation (Nagaoka et al., 2000; Nemazee and Weigert, 2000).
The mouse model we tried to generate differs from the ones previously described in two
basic points: a) it assays directly the functionality of the RAG recombinase (for which
both RAG1 and RAG2 have to be expressed) and not just activity of the promoter
regions and b) if recombination of the substrate occurs the reporter is not transiently
expressed but the cells are constitutively labelled.
Since the purpose of the experiment is to label cells that express RAG proteins in the
periphery, recombination of the substrate should not occur in the bone marrow. V(D)J
recombination does not affect all loci present in a cell, suggesting that there are potential
ways to target recombination to specific substrates or regulate the recombination event
temporally. Transcription of endogenous Ig and TCR loci seems to correlate well with
onset of recombination (Yancopoulos and Alt, 1985)(Goldman et al, 1993) while
transcription of VH elements is not detected in cell lines unable to perform VH to DHJH
recombination (Schlissel, Corcoran and Baltimore, 1991). Therefore, insertion of the
reporter substrate into a transcriptionally inactive locus could be used as a potential
means to prevent recombination of the substrate during primary Ig rearrangement.
Activation of the locus later, in mature B cells, is necessary in order to allow
recombination in case of RAG re-expression
The CD21 gene was the only reported example which displayed the desired gene
expression profile: no expression (within detection limits) in bone marrow B cells, but
constitutive expression in almost all later stages of the B cell life cycle (Hu et al., 1997).
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For this reason, and after analysis of CD21 mRNA in sorted B cell populations we
decided to target the CD21 gene for insertion of the recombination substrate.
Insertion of the recombination substrate into the CD21 locus could be a problem since
the CD21 gene is thus disrupted. Targeted disruption of the CD21 gene is known to
impair humoral immune responses and germinal centre formation (Ahearn et al., 1996;
Molina et al., 1996). However, only one allele is mutated in the reporter mice and
abrogation of one copy of the gene does not affect germinal centre formation. PNA
positive B cells, derived from targeted ES cells, were indeed found after immunisation in
the chimeras analysed.
Although the general opinion is that transcriptionally silent substrates are refractory to
recombination (reviewed in Sleckman, Gorman and Alt, 1996) there have been reports
of rearrangement in the absence of detectable transcription (Kallenbach et al., 1993)
(Lauster et al., 1993) (reviewed in Lewis, 1994)]. The possibility that recombination of
the substrate would occur in the bone marrow, despite the choice of a transcriptionally
‘inactive’ locus for insertion, could not be excluded. Recombination could also occur in
the thymus, where the RAG proteins are expressed for TCR assembly. However, in the
chimeras analysed, there was no detectable GFP expression in bone marrow B cells, or
inversion at the genomic level in thymus (Figure 14) and bone marrow (Figure 19, 20).
Therefore recombination does not occur when the RAG recombination machinery is
actively rearranging Ig and TCR loci. This in itself is an interesting observation;
recombination signal sequences have been characterised as the DNA elements, which
are recognised by the RAG proteins (Difilippantonioet al., 1996; Sakano et al., 1979)
and can be cleaved by the RAG1/RAG2 complex in vitro (Ramsden, Paull and Gellert,
1997). RSSs are also sufficient in mediating V(D)J recombination of extrachromosomal
substrates (Hesse et al., 1987) (Lieber et al., 1988), but it is still not clear whether they
alone can direct V(D)J recombination outside Ig and TCR loci, in a locus not usually
targeted for V(D)J recombination. Most transgenic substrates analysed for V(D)J
recombination are in fact Ig and TCR mini-loci (McMurry et al., 1997) containing not
just the RSS sequences but additional enhancer/promoter elements present in these loci .
These elements might affect or even be necessary for targeting recombination to specific
DNA regions (Engleret al., 1991; Lauster et al., 1993). Only recently there was a report
of an episomal, ‘chromatinized’ substrate containing only RS sequences and a luciferase
reporter gene, which was able to undergo V(D)J recombination (Cherry and Baltimore,
1999); still an episomal substrate might not fully mimic the genomic situation. However,
in the CD21-GFP-RAG reporter mice generated, the RSS are integrated in the genome
and are unable to recombine in developing B and T cells. This suggests, in accord with
the accessibility hypothesis, that only the presence of RSS in a locus is not sufficient for
V(D)J recombination at this locus to occur. Possibly additional elements present in Ig
and TCR loci are necessary for V(D)J recombination, although the elements
characterised to date are all related to transcriptional activation of these loci. Therefore,
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transcriptional activation of the CD21 gene might render the requirement for Ig or TCR
enhancer/promoter elements redundant and allow recombination of the RSS sequences
embedded in this locus to occur.
Lack of GFP expressing cells in the spleen or detectable inversion at the genomic level
by southern blot analysis or by PCR (Figures 17-20 ) indicates that RAG recombination
does not occur in peripheral B cells either, where the CD21 gene is expressed. Again,
this could be an indication of the inability of RSS alone to target V(D)J recombination
outside the normally recombining Ig and TCR loci or insufficient RAG expression in
peripheral B cells. The latter possibility would be in accordance with observations from
the RAG expression reporter mice (Gartner et al., 2000;Kuwata et al., 1999; Nagaoka et
al., 2000; Nagaoka, Yu and Nussenzweig, 2000), in which no RAG re-induction was
detected in peripheral B cells However, the requirement of additional elements for
V(D)J recombination of the chromosomal CD21-reporter substrate cannot be excluded.
It would therefore be interesting to test recombination ability of the CD21 integrated
substrate. A plasmid substrate containing identical recombination signal sequences and
the same reporter gene, as the ones inserted in the CD21 locus, can recombine in tissue
culture cells when co-transfected with RAG expression vectors. But as previously
mentioned V(D)J recombination of an extrachromosomal substrate and a genomic
substrate could be subject to different limitations. Therefore V(D)J recombination
potential of the CD21-reporter substrate should be analysed, either by transfecting
mature B cells from the CD21-GFP RAG reporter mice with RAG expression vectors or
inducing RAG protein expression by stimulating mature B cells. Transfection of mature
B cells however is experimentally demanding (Li, Wickham and Keegan, 2001) and
although RAG induction had been described in ex vivo isolated cells when treated with
LPS and IL4, no GFP expression was detected in B cells from the RAG-GFP reporter
mice upon similar treatment (Yu et al., 1999). In fact no recombination was detected in
cultured B cells from the CD21-GFP reporter chimeras when treated with LPS and IL-4
(Figure 19). It was not tested whether under these experimental conditions RAG proteins
were produced or whether CD21 gene expression was affected in these cells.
In an effort to overcome this problem, a B cell hybridoma line was generated from LPS
activated B cells derived from one of the chimeras. Hybridoma clones were screened for
CD21 expression; on most clones analysed CD21 expression is not uniform (some cells,
but not all express CD21) which could be an indication that hybridoma lines are down-
regulating CD21 gene expression. If some clones retain CD21 expression they could be
analysed for RAG mediated recombination, after transfection with RAG expression
vectors.
The inverse approach is also interesting. Induction of CD21 transcription in RAG
expressing (pro- and pre-) B cells could potentially stimulate recombination of the
substrate. Recently it has been reported that demethylation by treatment of cells with the
methyltransferase inhibitor 5’-aza-2-deoxycytidine induces CD21 transcription.
Trichostatin A (TSA), a histone deacetylation inhibitor also induces transcription in
progenitor B cells (Schwab and Illges, 2001). If CD21 transcription in bone marrow B
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cells was induced then RAG mediated recombination could be ‘allowed’ to proceed in
the CD21 integrated locus.
In brief, analysis of the CD21-GFP RAG reporter strain showed that:
-there is no V(D)J recombination of a reporter substrate inserted into the CD21 locus in
bone marrow and thymus.
-V(D)J recombination does not occur in peripheral B cells within the detection limit of
our assay (more than 10-20% of cells from different sorted fractions should have
inverted the substrate in order to be detectable by PCR, see Figure 20).
4.2 V(D)J recombination and transcription
Ideally we would have liked to assess the relation of transcription and V(D)J
recombination in CD21 targeted mice. Another way to investigate relation of
transcription and V(D)J accessibility control is by using an inducible expression system.
Recombination could then be assayed in this system before and after addition of the
transcriptional inducer.
Initially, the interferon inducible Mx promoter (Kuhn et al., 1995) was tested for this
purpose but inducibility was poor as analysed either with a luciferase based assay or
with a GFP reporter construct. The tetracycline responsive element (TRE) or tetracycline
inducible promoter has been well characterised in several cell culture systems (Gossen,
Bonin and Bujard, 1993; Gossen and Bujard, 1992; Gossen et al., 1995). A HeLa cell
line, which contains the regulatory elements for tetracycline induced transcription
(reverse transactivator rtTA) and has been tested for good inducibility and low
background expression levels was used.
The V(D)J recombination substrate was stably integrated in the cells by puromycin
selection. The puromycin resistance gene functions additionally as a translational stop
cassette (Angrand et al., 1998) and being flanked by Recombination Signal Sequences
can be removed by RAG recombination. The poly-adenylation signal of the puromycin
gene is sufficient to prevent GFP production, since no GFP expressing cells can be
detected in isolated clones prior to transfection with RAG expression vectors.
Of the 18 isolated clones only three expressed GFP after transient transfection with RAG
expression vectors. There could be several reasons for this; although control transfection
of HeLa cells with a CMV-EGFP reporter gene was generally efficient (~50%
transfection efficiency) the cotransfection efficiency of the two RAG expression vectors
nor the expression levels of RAG1, RAG2 proteins after transfection could be
determined. Additionally, the clones were selected on the basis of puromycin resistance
but were not analysed for integration of the GFP gene nor for the number of copies
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integrated. If more than one copies of the substrate are integrated in a head-to-tail
configuration, as is often the case with DNA transgenes, a number of RSSs will be
present in this region. In that case recombination between any of the tandemly arranged
RSSs can occur and will give unpredictable products, possibly not resulting in GFP
expression. Furthermore, tandemly repeated arrays of genes have been implicated in
silencing of a locus by condensation into heterochromatin (Dorer and Henikoff, 1997).
Two of the three clones were analysed further for relation of induction of transcription
and RAG recombination. In the first clone, GFP expressing cells were detected only
when transfection with the RAG expression vectors was performed in the presence of
the transcriptional inducer (doxycycline). In the second clone however, GFP expressing
cells were present even when transfection was performed in the absence of doxycycline
and (theoretically) active transcription of the substrate. The percentage of GFP+ cells in
this clone after RAG transfection was higher than that observed in the first clone. Tet
transactivation is sensitive to position effects and basal transcriptional activity in the
absence of the inducer can vary depending on the integration site of the substrate (H.
Bujard, personal communication). It should be noted, that the cells were selected on the
basis of puromycin resistance, and thereby high expression of the puromycin
acetyltransferase (PAC) gene by the Tet-Operator. So in a way ‘leakiness’ is favoured in
this system and could affect RAG accessibility to the substrate. It would be therefore
informative to use the bi-directional Tet promoter (Baron et al., 1995) and screen clones
on one hand for puromycin resistance (and therefore high levels of expression) as
before, but with another reporter gene (i.e. luciferase, which is transcribed in the
opposite orientation) eliminate clones with high basal transcription.
The clones that have already been generated could also be analysed for basal
transcription levels in the absence of doxycycline, either by RT-PCR and amplification
of PAC transcripts or by monitoring survival of the cells with increasing concentration
of puromycin.
Another surprising observation was that in Clone#2 the percentage of GFP expressing
cells is in fact higher in the absence of doxycycline. This could reflect differences either
in transfection efficiency (although there have been no reports of doxycycline affecting
transfection efficiencies) or expression of the RAG proteins. Indeed, tetracyclines have
been reported to down-regulate expression of endogenous genes in certain systems
(Amin et al., 1997; Kuzin et al., 2001).
From the preliminary analysis of the Tet inducible lines it was shown:
-that RSS sequences are able to recombine when inserted in a genomic locus. The
recombination efficiency however is low (up to 2%). Comparing RAG recombination
efficiencies in an extrachromosomal and the stably integrated substrate would be
interesting. Efficiency of recombination could be affected by addition of enhancer or
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promoter elements from the Ig locus (Engler et al., 1991). although the IgH enhancer
does not affect recombination of plasmid substrates (Hesseet al., 1987).
 -that V(D)J recombination can be prevented by absence of a transcriptional inducer but
this is not always the case.
4.3 Establishment of allelic exclusion in the µMT mouse
Targeted disruption of the IgM membrane exons (µMT mouse) results in an almost
complete block in B cell development at the pre-B cell stage (Kitamura et al., 1991). In
heterozygous mutant mice normal numbers of cells are produced but loss of heavy chain
allelic exclusion is observed (Kitamura and Rajewsky, 1992). If V(D)J rearrangement on
the mutant allele is productive, soluble µ chain is expressed. The secreted µ chain
however, does not prevent VH→DHJH joining on the wild-type IgH allele, and cells
expressing two different µ chains (only one of which is membrane bound) can be
detected. These cells are termed double producers and are found at a higher than
expected frequency (25% instead of 12.2%) in heterozygous µMT mice. Assuming that
the frequency of productive VHDHJH joints is 1/3 and that allelic exclusion in these mice
was established upon pre-BCR expression from the wild-type allele, the expected
frequency of double producers would be 16.7% (10/60). Taking into consideration that
80% of rearrangements when DH segments are joined to JH segments in reading frame 3
(RF3) are non-productive (Gu, Kitamura and Rajewsky, 1991; Ichihara et al., 1989),
would further reduce the expected frequency of double producers to 12.2%. This
situation is schematically demonstrated in Figure A assuming that allelic exclusion is
established upon pre-BCR expression (and rearrangements stop at the point indicated by
the dashed vertical line). However, the frequency of double producers observed in LPS
activated bone marrow cultures was close to 25% (Kitamura and Rajewsky, 1992). Two
theories were proposed to explain the observed discrepancy, both of which consider the
effect of the actively transcribing neomycinr gene on the rearranging IgH locus.
Either the neomycinr containing allele in heterozygous µMT mice is not subject to allelic
exclusion and VH→DHJH joining on this allele can occur as long as the RAG proteins are
expressed (regardless of pre-BCR signalling) (Figure 30A) or VH to DHJH rearrangement
on the neomycinr containing allele is favoured and occurs first in pro-B cells (Figure
30B). Since rearrangement of this allele cannot lead to pre-BCR expression and
signalling, rearrangement will always proceed on the other allele.
The two possibilities are depicted in Figure 30. In both cases the observed number of
double producers would be identical (approximately 20/60 = 30%). Correcting again for
non-productive rearrangements due to stop codons in RF3 joints, the expected frequency
of double producers in heterozygous µMT mice would be 24.4% in both cases. This is in
accord with the observed frequency of double producers in bone marrow B cells (~25%).
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Figure 30: Potential rearrangement of the µMT targeted allele in case of A) breakdown of allelic
exclusion or B) preferential rearrangement of the targeted allele before allelic exclusion is
established. Starting from an indicative population of 180 cells, numbers indicate cells that survive;
all of these need have a productive rearrangement on their WT allele. VDJ+ indicates productive
rearrangements while VDJ both productive and non productive joints. Numbers in brackets refer to
cells that have a productive rearrangement on the neor containing allele. Dashed lines designate the
point at which pre-BCR signalling and allelic exclusion should be established.
In order to discriminate between the two possibilities and assess whether allelic
exclusion can indeed be established on the µMT allele we decided to analyse the process
in a context which promotes allelic exclusion.
Transgenic mice expressing an Ig heavy chain were found to inhibit rearrangement of
endogenous IgH loci (Weaver et al., 1985); similarly heavy chain insertion mice contain
a pre-rearranged VHDHJH element targeted into the IgH locus and can also inhibit
rearrangement of the second allele (Taki, Meiering and Rajewsky, 1993) One such
heavy chain insertion mouse mutant, the glD42 strain (Pewzner-Junget al., 1998), can
produce secreted IgM distinguishable from the one produced from the µMT allele by
allotypic differences. The µMT/glD42 cross was therefore generated to analyse the
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effect of the neomycinr gene in a situation where IgH allelic exclusion does not require
V(D)J rearrangement and double producers can be detected by a simple anti-allotypic
staining. If expression of the glD42 encoded pre-BCR on the surface of the cells is
sufficient to prevent rearrangement of the neor containing allele, no double producers
should be detected in these mice.
 Indeed, no double producers were present in ex vivo  (LPS activated) cultures of cells
from spleen and bone marrow from glD42/µMT, as assessed by flow cytometric analysis
and on slide stainings. Additionally no antibody production from the µMT allele is
detectable in the sera of these mice. The neomycinr containing allele is therefore subject
to allelic exclusion and not rendered constitutively accessible for recombination. The
observed number of double producers, in the bone marrow of the µMT heterozygous
mice, could be generated due to preferential rearrangement of the neomycinr containing
allele upon the onset of V(D)J recombination in pro-B cells. Once an IgH heavy chain is
expressed on the surface of the cells however, rearrangement stops and allelic exclusion
is established irrespective of the presence of an actively transcribed gene in the IgH
locus.
Analysis of the genomic IgH locus also supports this model. In the glD42/µMT cross
there is no significant loss of DFL16 probe signal* (Table 5, Figure 27), which would be
indicative of VH→ DHJH rearrangement. DH →JH rearrangement does occur in B cells
from these mice, but still at a lower level compared to WT or µMT heterozygous mice
(as assessed by southern blot analysis using the DQ52 probe). In the latter two cases the
DQ52 signal is undetectable, while the glD42/µMT B cells show a five-fold reduction
compared to non-B cells. But DH→JH joining is not subject to allelic exclusion and
usually occurs on both IgH alleles (Alt et al., 1984) while DHJH joints have been
detected in developing T cells (Born et al., 1988). Loss of DQ52 signal was indeed
evident by analysis of DNA from thymus of glD42/µMT mice. The µMT allele is ‘open’
for DH→ JH recombination but VH→ DHJH joining is inhibited by expression of the pre-
BCR.
Another point of interest is the extent of V(D)J rearrangement in µMT heterozygous
mice. The observed number of double producers (25%) in bone marrow of these mice
would indicate that virtually all B cells harbour a VHDHJH rearrangement on both alleles.
Roughly 25% of the rearrangements would be productive in a non-selective situation,
and this is indeed detected at the protein level (secreted antibody from LPS activated
bone marrow cells, see Figure 24) in µMT/C57BL6 mice. Southern blot analysis
however of DNA from sorted B220+ splenic cells from these mice does not show
complete loss of the DFL16 probe signal .The signal is strongly reduced (more than in
the respective population from wildtype mice), to the extent that precise quantification is
difficult; the reduction of the DFL16 probe signal ranges from 5- to 10-fold, suggesting
that 20%-40%** of B cells have no VH→ DHJH rearrangement on the µMT allele. Similar
analysis of wild-type B cells shows that ~60% of the cells have no VH→  DHJH
rearrangements on the second IgH locus. It seems that a higher fraction of B cells in the
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µMT heterozygous mice harbour VHDHJH rearrangements on both alleles compared to
wild-type mice, but not all.
It should be considered that the observed number of double producers in the spleen of
heterozygous µMT mice is much lower than in the bone marrow (6% compared to 25%
respectively (Kitamura and Rajewsky, 1992) (Table4 in Results). Possibly most bone
marrow B cells harbour VHDHJH rearrangements on both alleles (slightly more than 2/3
of which are non-productive on the µMT allele) but during transition to the peripheral B
cell pool, cells expressing two different antibodies (even though a BCR of a unique
specificity is expressed) are not favoured. Toxicity of free immunoglobulin heavy chain
has been proposed as a mechanism for counterselection of double producers (Kohler,
1980) although double-heavy chain insertion mice have normal numbers of B cells and
retain expression of both IgH heavy chains (Sonodaet al., 1997). Another possibility is
that competition of the two heavy chains for IgL chain pairing, leads to reduced BCR
surface density and impaired survival of these cells (Sanchez et al., 2000). Single IgH
expressing cells which contain a non-productive rearrangement of the µMT allele or no
rearrangement on this allele would then be favoured. Analysis of the serum levels of
antibody generated from the µMT allele (IgMa allotype) also supports the finding that
double producers are counterselected. IgMa antibodies are detectable in µMT
heterozygous mice but the amount of IgMa antibodies is only 5% of the total IgM (IgMa
+IgMb antibody present in the sera). This estimate would be in accordance with the
observed frequency of double producers in the spleen.
It would be interesting to analyse bone marrow fractions from µMT heterozygous mice,
for genomic rearrangement first to see if the observed 25% of double producers really
reflects VH→  DHJH rearrangement of both IgH alleles and if so at which stage these
double producers are counterselected.
Taken together analysis of the glD42/µMT mice showed that:
-no double producers were present in bone marrow and spleen of these mice by
intracellular staining after LPS activation
-no secreted antibody from the µMT allele was detected
in the IgH locus is not sufficient to overcome inhibition of VH to DHJH joining. On the
contrary, it would be interesting to check whether transcription of the neomycinr gene is
affected after pre-BCR signalling and allelic exclusion is established. -no VH→ DHJH
rearrangement was detected in splenic B cells. Therefore allelic exclusion is established
in the glD42/µMT mice, irrespective of the presence of the neomycinr gene in the IgH
locus. The question of the mechanism of establishment of allelic exclusion remains
open, but insertion of an exogenous promoter in the Ig locus is not sufficient for
maintenance of the accessible conformation of the locus after an IgH heavy chain has
been produced. .
----------------------------------------------------------------------------------------------------------------------------------------------------------------
* loss of DFL16 and DQ52 probe signal was determined by comparison of normalised signal from B220+
and B220- cells according to the formula:
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where D probe signal represents the reduction of intensity of DFL16 or DQ52 probe signal; DB220+ and
DB220- is the intensity of the signal from either of the two D probes and from DNA of B220
+ and B220-
cells respectively and C the intensity of the probe used for DNA quantification of each sample (CD21
probe or RH probe).
** Considering that x B220- cells (which have no rearrangement on either of the two IgH alleles) contain
2x copies of ‘D probe recognition sequence’ while B cells need to have one productive rearrangement on
the IgH locus (and therefore can contain only x ‘D probe recognition sequences’). Some B cells have
VHDHJH rearrangements on bothe alleles; if α is the fraction of cells which have VHDHJH joints on both
IgH alleles the above equation can be written as
D probe signal =(1-α)x/2x from which the percentage (2D%) of cells that harbour only one VHDHJH
rearrangement can be calculated
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5. Summary
Recombination activating gene proteins (RAG1 and 2) mediate antigen receptor
assembly in bone marrow B cells but their expression has also been reported in
peripheral B cells. To study the role of this late RAG expression an indicator mouse
strain was generated, which would allow labeling of cells that display V(D)J
recombination activity after bone marrow rearrangement has been completed. In the
mouse line generated (CD21-GFP RAG) a RAG recombination reporter substrate was
integrated in the CD21 locus. The idea was that recombination of the reporter substrate
in the bone marrow could be prevented by insertion in the CD21 locus, since the CD21
gene is transcriptionally inactive during bone marrow development and is mainly
expressed in mature B cells.
Indeed in the CD21-GFP RAG reporter mice no recombination was observed in bone
marrow B cells and T cells. Incorporation of RSSs in the CD21 locus is not sufficient for
V(D)J recombination to occur even though the RAG proteins are expressed.
Recombination was also not detected in mature B cells, although the CD21 locus is
transcriptionally active. This could be due to insufficient RAG expression in peripheral
B cells to allow V(D)J recombination of the artificial substrate. However, it cannot be
excluded that RAG-mediated recombination of genomic substrates requires the presence
of additional regulatory elements.
Attempts to analyse dependence of RAG mediated recombination on transcription, using
an inducible gene expression system, were also made. Induction of transcription
potentiates RAG-mediated recombination of a stably integrated reporter substrate in one
case analysed; however absence of the inducer is not limiting for V(D)J recombination
in another situation.
Accessibility control of V(D)J recombination is also important for allelic exclusion,
which is established in B cells as a partial block of IgH rearrangement. In a mutant
mouse containing a neomycinr gene, inserted in the IgM membrane region (µMT
mouse), the frequency of B cells expressing two IgH chains is higher than expected. A
rearranged heavy chain however is able to prevent rearrangement of the µMT alelle
suggesting that allelic exclusion is properly established despite of the presence of an
exogenous promoter in the IgH locus.
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6. Zusammenfassung
Die Proteine RAG1 und RAG2 (Recombination Activating Gene Protein) vermitteln die
Umlagerung der Antigenrezeptorgene im Knochenmark. Allerdings wurde auch in
peripheren B Zellen RAG1 und 2 Proteinexpression gefunden. Um die Funktion dieser
späten RAG-Ausprägung zu untersuchen, wurde ein Indikator-Mausstamm (CD21-GFP
RAG) generiert. In diesem Mausstamm sollten B Zellen markiert werden, in denen
V(D)J Rekombination nach Abschluss der Umlagerungen im Knochenmark
stattgefunden hat. Zu diesem Zweck wurde ein RAG-Rekombinationssubstrat durch
homologe Rekombination in den CD21 Lokus der Maus eingebracht.
Umlagerung und Ausprägung des Reportergens sollten auf Zellen beschränkt werden,
die die RAG Proteine nach vollständiger Immunglobulinumlagerung re-exprimieren. Da
es Anzeichen dafür gibt, dass Rekombination von Transkription abhängt, schien ein
Weg, dieses Ziel zu erreichen, die Einbringung des Reporter-Konstruktes in den CD21
Lokus. Dieser wird während der Reifung der B Zellen im Knochenmark nicht
transkribiert und wird hauptsächlich in reifen B Zellen ausgeprägt.
In den CD21-GFP RAG Mäusen wurden tatsächlich keine Umlagerung des
Reportergens in B Zellen des Knochenmarks oder T Zellen detektiert. Dies zeigt, dass
trotz vorhandener RAG Protein-Ausprägung in den CD21 Lokus eingebrachte RSS
Sequenzen nicht rekombiniert werden. Rekombination des Substrats konnte allerdings
auch in reifen B Zellen nicht nachgewiesen werden, obwohl in ihnen das CD21 Gen
exprimiert wird. Dies könnte daran liegen, dass die RAG-Expression in der Peripherie
nicht ausreicht, um V(D)J Umlagerung eines transgenen Substrats zu vermitteln. Es
kann aber nicht ausgeschlossen werden, dass zur RAG-vermittelte Rekombination von
genomischen Substraten das Vorhandensein von zusätzlichen regulatorischen Elementen
notwendig ist.
Es wurde auch versucht, die Abhängigkeit RAG-vermittelter Umlagerungen von
Transkription anhand induzierbarer Genexpression in Zelllinien zu demonstrieren.
Leider kann keine eindeutig Aussage getroffen werden, da in einer Zelllinie
Rekombination tatsächlich nur nach Gabe von Induktor erfolgte, in einer anderen
Zelllinie war V(D)J Rekombination dagegen unabhängig von Induktion der
Genexpression.
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Die Limitierung von V(D)J Rekombination durch Lokuszugänglichkeit ist auch wichtig
für die Allelische Exklusion, die einen partiellen Block von IgH Umlagerungen darstellt.
In einer Mausmutante, die eine Neomyzinresistenzkasette in der Transmembranregion
eines Allels (µMT Allel) des IgM Gens enthält, wurde eine erhöhte Anzahl von B Zellen
die zwei IgH Moleküle ausprägen, gefunden. Eine vollständig umgelagerte schweren
Kette auf dem anderen Allel verhindert die Umlagerung des µMT Allels. Dies zeigt,
dass Allelische Exklusion trotz Vorhandensein eines transgenen Promoters in dem IgH
Lokus etabliert werden kann.
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